Compounds and conjugates thereof
By developing topoisomerase inhibitor derivative targeting conjugates that can cleave linker linkage linkage, the problems of low drug release efficiency and insufficient targeting ability in the prior art are solved, and efficient therapeutic effects on specific cells are achieved.
Patent Information
- Application Number
- CN202311084298.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-22
- Filing Date
- 2020-03-23
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-03-23
AI Technical Summary
Existing topoisomerase inhibitors have low drug release efficiency in the treatment of cancer and autoimmune diseases, resulting in poor therapeutic effects and the prior art is difficult to effectively target specific cell types.
A targeted conjugate containing topoisomerase inhibitor derivatives was developed to link to amino residues through a cleavable linker, using antibodies as ligand units to achieve efficient binding and drug release to specific target molecules.
It improves the release efficiency and efficacy of drugs in target cells, enhances the targeting ability of specific cell types, and provides new methods for the treatment of proliferative and autoimmune diseases.
Smart Images

Figure CN117263948B_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application with application date of March 23, 2020, application number 202080025199.7, and invention name “Compounds and Conjugates Thereof”. Technical Field
[0002] The present invention relates to targeted conjugates comprising specific topoisomerase inhibitors and compounds useful for their synthesis, as well as released warheads. Background Art
[0003] Topoisomerase inhibitors
[0004] Topoisomerase inhibitors are chemical compounds that block the action of topoisomerases (topoisomerase I and II), a type of enzyme that controls changes in DNA structure during the normal cell cycle by catalyzing the breaking and rejoining of the phosphodiester backbone of DNA chains.
[0005] The following compounds:
[0006]
[0007] (in racemic form) disclosed in EP 0296597 (Example 63). Also disclosed in Sugimori, M., et al., J Med Chem, 1998, 41, 2308-2318 (DOI: 10.1021 / jm970765q) (compound 34 in racemic form), where its biological activity and that of some related compounds are discussed.
[0008] Various topoisomerase inhibitors, such as irinotecan and exatecan derivatives and doxorubicin, have been included in antibody-drug conjugates. For example, Daiichi Sankyo has used DS-8201a in clinical trials:
[0009]
[0010] Wherein the antibody is Her2 (Takegawa, N., et al., Int J Cancer, 2017, 141, 1682-1689 (DOI: 10.1002 / ijc.30870). The ADC releases an exatecan derivative:
[0011]
[0012] Burke, PJ, et al., Bioconjugate Chem., 2009, 20, 1242-1250, disclose the following conjugates:
[0013]
[0014] They are linked via the amino group to the following structures:
[0015]
[0016] These include the PABC (p-aminobenzyloxycarbonyl) group.
[0017] Immunomics researchers have used govetican-saxetuzumab (IMMU-132) in clinical trials (Cardillo, TM, et al., Bioconjugate Chem, 2015, 26(5), 919-931, DOI: 10.1021 / acs.bioconjchem.5b00223)
[0018] Summary of the invention
[0019] In a general aspect, the present invention provides a conjugate comprising the following topoisomerase inhibitor derivative (A*, Drug unit):
[0020]
[0021] A linker is provided for connecting a Ligand unit, wherein the linker is attached to an amino residue in a cleavable manner. The Ligand unit is preferably an antibody. The present invention also provides A* with an attached Linker unit, intermediates for its synthesis, and released warheads.
[0022] A first aspect of the present invention comprises compounds having Formula I:
[0023]
[0024] and its salts and solvates, wherein R L is a linker for attachment to the Ligand unit, the linker being selected from:
[0025] (ia):
[0026]
[0027] in
[0028] Q is:
[0029] Where QX such that Q is an amino acid residue, a dipeptide residue, a tripeptide residue or a tetrapeptide residue;
[0030] X is:
[0031]
[0032] Wherein a=0 to 5, b1=0 to 16, b2=0 to 16, c1=0 or 1, c2=0 or 1, d=0 to 5, wherein at least b1 or b2=0 (i.e., only one of b1 and b2 may not be 0) and at least c1 or c2=0 (i.e., only one of c1 and c2 may not be 0);
[0033] G L is a linker for attachment to the Ligand unit;
[0034] (ib):
[0035]
[0036] Where R L1 and R L2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropene or cyclobutene group; and
[0037] e is 0 or 1.
[0038] A second aspect of the present invention provides a method for preparing a compound of the first aspect of the present invention, the method comprising at least one of the method steps listed below.
[0039] In a third aspect, the present invention provides a conjugate having formula IV:
[0040] L-(D L ) p (IV)
[0041] or a pharmaceutically acceptable salt or solvate thereof, wherein L is a ligand unit (ie, a targeting agent), D L is a Drug Linker unit having Formula III:
[0042]
[0043] R LL is a linker connected to the Ligand unit, the linker being selected from
[0044] (ia'):
[0045]
[0046] wherein Q and X are as defined in the first aspect and G LL is a linker attached to the Ligand unit; and
[0047] (ib'):
[0048]
[0049] Where R L1 and R L2 is as defined in the first aspect; and
[0050] p is an integer from 1 to 20.
[0051] Therefore, the conjugate comprises a ligand unit covalently linked to at least one drug unit (A*) via a linker unit (i.e., a ligand unit to which one or more drug linker units are attached). The ligand unit described more fully below is a targeting agent that is combined with a target moiety. The ligand unit can, for example, specifically bind to a cell component (cell binding agent) or other target molecules of interest. Therefore, the present invention also provides a method for treating, for example, various cancers and autoimmune diseases. These methods encompass the use of conjugates, wherein the ligand unit is a targeting agent that specifically binds to a target molecule. The ligand unit can be, for example, a protein, a polypeptide or a peptide, such as an antibody, an antigen-binding fragment of an antibody, or other binding agents, such as an Fc fusion protein.
[0052] The drug loading is represented by p (the number of drug units per ligand unit (e.g., antibody). The drug loading per ligand unit (e.g., Ab or mAb) may range from 1 to 20 drug units (D). For a composition, p represents the average drug loading of the conjugate in the composition, and p ranges from 1 to 20.
[0053] The fourth aspect of the present invention provides use of the conjugate of the third aspect of the present invention in the manufacture of a medicament for treating a proliferative disease. The fourth aspect also provides the conjugate of the third aspect of the present invention for use in treating a proliferative disease.
[0054] One of ordinary skill in the art can readily determine whether a candidate compound treats a proliferative disorder of any particular cell type. For example, assays that can be conveniently used to assess the activity provided by a particular compound are described in the Examples below.
[0055] A series of ADCs are discussed in Nakada, et al., Bioorg Med Chem Lett, 26 (2016), 1542-1545 (DOI: 10.1016 / j.bmcl.2016.02.020):
[0056]
[0057] It is concluded that the reduced cytotoxicity of ADC (1) and (2) may be due to steric hindrance of the released drug moiety at the site of action of the degrading enzymes in the tumor cells. The document teaches the importance of separating the peptidic group from the bulk released drug moiety. In contrast, in the present invention, the peptidic group is directly attached to the bulk released drug moiety.
[0058] The fifth aspect of the present invention is compound A:
[0059]
[0060] As a single enantiomer or in enantiomerically enriched form.
[0061] The sixth aspect of the present invention is a compound having formula VI:
[0062]
[0063] wherein Q is as defined in the first aspect.
[0064] definition
[0065] C 5-6 Arylene: As used herein, the term "C 5-6 "Arylene" refers to a divalent moiety obtained by removing two hydrogen atoms from an aromatic ring atom of an aromatic compound.
[0066] In this article, a prefix (such as C 5-6 ) represents the number of ring atoms or a range of numbers of ring atoms, whether carbon atoms or heteroatoms.
[0067] The ring atoms may all be carbon atoms, as in a "carboarylene group", in which case the group is phenylene (C 6 ).
[0068] Alternatively, the ring atoms may include one or more heteroatoms, as in a "heteroarylene group." Examples of heteroarylene groups include, but are not limited to, those derived from:
[0069] N 1 :Pyrrole (azole) (C 5 ), pyridine (azine) (C 6 );
[0070] O 1 :Furan (oxole) (C 5 );
[0071] S 1:Thiophene (thiole) (C 5 );
[0072] N 1 O 1 :Oxazole (C 5 ), isoxazole (C 5 ), isoxazine (C 6 );
[0073] N 2 O 1 :Oxadiazole (furazan) (C 5 );
[0074] N 3 O 1 :Oxatriazole (C 5 );
[0075] N 1 S 1 :Thiazole (C 5 ), isothiazole (C 5 );
[0076] N 2 :Imidazole(1,3-oxadiazole)(C 5 ), pyrazole (1,2-oxadiazole) (C 5 ), pyridazine (1,2-diazine) (C 6 ), pyrimidine (1,3-diazine) (C 6 ) (e.g., cytosine, thymine, uracil), pyrazine (1,4-diazine) (C 6 );as well as
[0077] N 3 :Triazole (C 5 ), triazine (C 6 ).
[0078] C 1-4 Alkyl: As used herein, the term "C 1-4 "Alkyl" refers to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 4 carbon atoms, which hydrocarbon compound may be aliphatic or alicyclic, and may be saturated or unsaturated (e.g., partially unsaturated, fully unsaturated). As used herein, the term "C 1-n "Alkyl" refers to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to n carbon atoms, which hydrocarbon compound may be aliphatic or alicyclic, and may be saturated or unsaturated (e.g., partially unsaturated, fully unsaturated). Thus, the term "alkyl" includes the subclasses discussed below: alkenyl, alkynyl, cycloalkyl, etc.
[0079] Examples of saturated alkyl groups include, but are not limited to, methyl (C 1 ), ethyl (C 2 ), propyl (C 3 ) and butyl (C 4 ).
[0080] Examples of saturated straight chain alkyl groups include, but are not limited to, methyl (C 1 ), ethyl (C 2 ), n-propyl (C 3 ) and n-butyl (C 4 ).
[0081] Examples of saturated branched alkyl groups include isopropyl (C 3 ), isobutyl (C 4 ), sec-butyl (C 4 ) and tert-butyl (C 4 ).
[0082] C 2-4 As used herein, the term "C 2-4 "Alkenyl" refers to an alkyl group having one or more carbon-carbon double bonds.
[0083] Examples of unsaturated alkenyl groups include, but are not limited to, ethenyl, vinyl (-CH=CH 2 ), 1-propenyl (-CH=CH-CH 3 ), 2-propenyl (allyl, -CH-CH=CH 2 ), isopropenyl (1-methylvinyl, -C(CH 3 )=CH 2 ) and butenyl (C 4 ).
[0084] C 2-4 Alkynyl: As used herein, the term "C 2-4 "Alkynyl" refers to an alkyl group having one or more carbon-carbon triple bonds.
[0085] Examples of unsaturated alkynyl groups include, but are not limited to, ethynyl (—C≡CH) and 2-propynyl (propargyl, —CH 2 -C≡CH).
[0086] C 3-4 Cycloalkyl: As used herein, the term "C 3-4 "Cycloalkyl" refers to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a cyclic hydrocarbon (carbocyclic) compound, the moiety having from 3 to 7 carbon atoms, including from 3 to 7 ring atoms.
[0087] Examples of cycloalkyl groups include, but are not limited to, those derived from:
[0088] Saturated monocyclic hydrocarbon compounds:
[0089] Cyclopropane (C 3 ) and cyclobutane (C 4 );as well as
[0090] Unsaturated monocyclic hydrocarbon compounds:
[0091] Cyclopropene (C 3 ) and cyclobutene (C 4 ).
[0092] Connection Tags: In Medium, superscript C(=O) and NH indicates the group to which the atom is bonded. For example, an NH group is shown bonded to a carbonyl group (which is not part of the depicted moiety), and a carbonyl group is shown bonded to an NH group (which is not part of the depicted moiety).
[0093] Salt
[0094] It may be convenient or desirable to prepare, purify, and / or handle the corresponding salts of the active compounds, such as pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts are discussed in Berge, et al., J. Pharm. Sci., 66, 1-19 (1977).
[0095] For example, if the compound is anionic, or has a functional group that can be anionic (e.g., -COOH can be -COO - ), then it can form a salt with an appropriate cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth metal cations such as Ca 2+ and Mg 2+ , and other cations such as Al +3 Examples of suitable organic cations include, but are not limited to, ammonium ions (i.e., NH 4 + ) and substituted ammonium ions (e.g. NH 3 R + NH 2 R 2 + 、NHR 3 + NR 4 +Some examples of suitable substituted ammonium ions are those derived from ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, and amino acids such as lysine and arginine. Common examples of quaternary ammonium ions are N(CH 3 ) 4 + .
[0096] If the compound is cationic, or has a functional group that can be cationic (e.g., -NH 2 It can be -NH 3 + ), then a salt may be formed with an appropriate anion. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfurous acid, nitric acid, nitrous acid, phosphoric acid, and phosphorous acid.
[0097] Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetoxybenzoic acid, acetic acid, ascorbic acid, aspartic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, ethylenediaminetetraacetic acid, ethanedisulfonic acid, ethanesulfonic acid, fumaric acid, glucheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxymaleic acid, hydroxynaphthoic acid, hydroxyethanesulfonic acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, methanesulfonic acid, mucic acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, pantothenic acid, phenylacetic acid, benzenesulfonic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, toluenesulfonic acid, trifluoroacetic acid, and valeric acid. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethylcellulose.
[0098] Solvate
[0099] The corresponding solvates of the active compound can be conveniently or desirably prepared, purified, and / or processed. The term "solvate" is used in the conventional sense herein to refer to a complex of a solute (e.g., an active compound, a salt of an active compound) and a solvent. If the solvent is water, the solvate can be conveniently referred to as a hydrate, such as a monohydrate, a dihydrate, a trihydrate, etc.
[0100] Isomers
[0101] Certain compounds of the present invention may exist in one or more specific geometric, optical, enantiomeric, diastereomeric, epimeric, atropisomeric, stereoisomeric, tautomeric, conformational or anomeric forms, including, but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r-forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; cis- and trans-forms; syncline- and anticline-forms; α- and β-forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and half-chair-forms; and combinations thereof, hereinafter collectively referred to as “isomers” (or “isomeric forms”).
[0102] The term "chiral" refers to molecules that have the property of non-superimposability of their mirror image partner, whereas the term "achiral" refers to molecules that are superimposable on their mirror image partner.
[0103] The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
[0104] "Diastereomers" refers to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity. Mixtures of diastereomers can be separated under high resolution analytical procedures such as electrophoresis and chromatography.
[0105] "Enantiomers" refers to two stereoisomers of a compound that are non-superimposable mirror images of each other.
[0106] The stereochemical definitions and conventions used herein generally follow those of SP Parker, ed., McGraw-Hill Dictionary of Chemical Terms (1984), McGraw-Hill Publishers, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. The compounds of the present invention may contain asymmetric or chiral centers and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the present invention (including but not limited to diastereomers, enantiomers and atropisomers and mixtures thereof, such as racemic mixtures) form part of the present invention. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane polarized light. When describing an optically active compound, the prefixes D and L, or R and S are used to indicate the absolute configuration of the molecule about its one or more chiral centers. The prefixes d and l or (+) and (-) are used to indicate the sign of rotation of plane polarized light by the compound, where (-) or l indicates that the compound is levorotatory. Compounds with the (+) or d prefix are dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. Specific stereoisomers may also be referred to as enantiomers, and a mixture of such isomers is often referred to as an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, and they can occur where there is no stereoselectivity or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
[0107] An "enantiomerically enriched form" refers to a sample of a chiral substance having an enantiomeric ratio greater than 50:50 but less than 100:0.
[0108] Note that, except for the discussion below regarding tautomeric forms, the term "isomer" as used herein specifically excludes structural (or constitutional) isomers (i.e., isomers that differ in the connectivity between the atoms rather than merely the position of the atoms in space). For example, the p-methoxy group (-OCH 3 ) should not be construed as referring to its structural isomer hydroxymethyl-CH 2 Similarly, reference to o-chlorophenyl should not be construed as a reference to its structural isomer m-chlorophenyl. However, reference to a class of structures is likely to include structural isomeric forms belonging to that class (e.g., C 1-7Alkyl includes n-propyl and isopropyl; butyl includes n-, iso-, sec- and tert-butyl; methoxyphenyl includes o-, m- and p-methoxyphenyl).
[0109] The above exclusion does not relate to tautomeric forms, such as keto, enol and enolic ester forms, such as, for example, the following tautomeric pairs: keto / enol (shown below), imine / enamine, amide / imino alcohol, amidine / enediamine, nitroso / oxime, thione / enethiol, N-nitroso / hyroxyazo and nitro / aci-nitro.
[0110]
[0111] The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions by reorganization of some valence electrons.
[0112] Note that the term "isomer" specifically includes compounds having one or more isotopic substitutions. For example, H may be in any isotopic form, including 1 H. 2 H(D), and 3 H(T); C can be in any isotopic form, including 12 C. 13 C. and 14 C; O can be in any isotopic form, including 16 O and 18 O; etc.
[0113] Examples of isotopes that may be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine and iodine, such as but not limited to 2 H (deuterium, D), 3 H (tritium), 11 C. 13 C. 14 C. 15 N. 18 F. 31 P. 32 P. 35 S. 36 Cl, and 125I. Various isotope-labeled compounds of the present invention, such as those into which radioactive isotopes such as 3H, 13C and 14C are incorporated. Such isotope-labeled compounds can be used for metabolic studies, reaction kinetic studies, detection or imaging techniques (such as positron emission tomography (PET) or single photon emission computed tomography (SPECT), including drug or substrate tissue distribution determination), or for radiotherapy of patients. In relation to distribution, metabolism and excretion (ADME), the deuterium-labeled or substituted therapeutic compounds of the present invention may have improved DMPK (drug metabolism and pharmacokinetics) properties. Substitution with heavier isotopes (such as deuterium) may provide certain therapeutic advantages (due to higher metabolic stability), such as increased in vivo half-life or reduced dosage requirements. 18F-labeled compounds can be used for PET or SPECT studies. Isotope-labeled compounds of the present invention and prodrugs thereof can generally be prepared by carrying out the methods disclosed in the schemes described below or in the examples and preparations, which replace non-isotope-labeled reagents with readily available isotope-labeled reagents. In addition, substitution with heavier isotopes, especially deuterium (i.e., 2H or D), can provide certain therapeutic advantages (due to greater metabolic stability), such as increased in vivo half-life or reduced dosage requirements or improvements in therapeutic index. It should be understood that deuterium is considered a substituent herein. The concentration of such heavier isotopes, especially deuterium, can be defined by an isotopic enrichment factor. In the compounds of the present invention, any atom not specifically designated as a particular isotope represents any stable isotope of that atom.
[0114] Unless otherwise indicated, references to a particular compound include all such isomeric forms, including (whole or partial) racemates and other mixtures thereof. Methods for the preparation (e.g., asymmetric synthesis) and separation (e.g., fractional crystallization and chromatographic means) of such isomeric forms are known in the art or are readily obtained by adopting the methods taught herein or known methods in a known manner.
[0115] Ligand unit
[0116] The ligand unit can be of any kind and includes proteins, polypeptides, peptides and non-peptide agents that specifically bind to the target molecule. In some embodiments, the ligand unit can be a protein, polypeptide or peptide. In some embodiments, the ligand unit can be a cyclic polypeptide. These ligand units can include antibodies or antibody fragments that contain at least one target molecule binding site, lymphokine, hormone, growth factor, or any other cell binding molecule or substance that can specifically bind to the target.
[0117] The terms "specifically bind" and "specific binding" refer to the binding of an antibody or other protein, polypeptide or peptide to a predetermined molecule (e.g., an antigen). Typically, an antibody or other molecule binds to a predetermined molecule at a specific binding affinity of at least about 1 x 10 7 M -1 The antibody binds to the predetermined molecule with an affinity that is at least two times greater than its affinity for binding to a nonspecific molecule (e.g., BSA, casein) but not to the predetermined molecule or a closely related molecule.
[0118] Examples of Ligand units include those agents described for use in WO 2007 / 085930, which is incorporated herein.
[0119] In some embodiments, the ligand unit is a cell binding agent that binds to an extracellular target on a cell. Such a cell binding agent can be a protein, polypeptide, peptide, or non-peptide agent. In some embodiments, the cell binding agent can be a protein, polypeptide, or peptide. In some embodiments, the cell binding agent can be a cyclic polypeptide. The cell binding agent can also be an antibody or an antigen-binding fragment of an antibody. Therefore, in one embodiment, the present invention provides an antibody-drug conjugate (ADC).
[0120] Cell Binding Agents
[0121] Cell binding agents can be of any kind and include peptides and non-peptides. These can include antibodies or antibody fragments containing at least one binding site, lymphokines, hormones, hormone mimetics, vitamins, growth factors, nutrient transport molecules, or any other cell binding molecule or substance.
[0122] Peptides
[0123] In one embodiment, the cell binding agent is a linear or cyclic peptide comprising 4-30, preferably 6-20 contiguous amino acid residues.
[0124] In one embodiment, the cell binding agent comprises a ν β 6 The peptide has an effect on α ν β 6 The selectivity can exceed XYS.
[0125] In one embodiment, the cell binding agent comprises an A20FMDV-Cys polypeptide. A20FMDV-Cys has the following sequence: NAVPNLRGDLQVLAQKVARTC. Alternatively, a variant of the A20FMDV-Cys sequence can be used, in which one, two, three, four, five, six, seven, eight, nine or ten amino acid residues are replaced by another amino acid residue. In addition, the polypeptide can have the sequence NAVXXXXXXXXXXXXXXXRTC.
[0126] Antibody
[0127] The term "antibody" herein is used in the broadest sense and specifically encompasses monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), multivalent antibodies, and antibody fragments, as long as they exhibit the desired biological activity (Miller et al. (2003) Jour. of Immunology 170:4854-4861). Antibodies can be murine, human, humanized, chimeric, or derived from other species. Antibodies are proteins produced by the immune system that are able to recognize and bind to specific antigens. (Janeway, C., Travers, P., Walport, M., Shlomchik (2001) Immuno Biology, 5th ed., Garland Publishing, New York). Target antigens typically have many binding sites, also called epitopes, that are recognized by CDRs on multiple antibodies. Each antibody that specifically binds to a different epitope has a different structure. Therefore, an antigen can have more than one corresponding antibody. Antibodies include full-length immunoglobulin molecules or immunologically active portions of full-length immunoglobulin molecules (i.e., molecules containing antigen binding sites that immunospecifically bind to target antigens of interest or portions thereof), such targets include but are not limited to cancer cells or cells that produce autoimmune antibodies associated with autoimmune diseases. Immunoglobulins can be any type (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecules. Immunoglobulins can be derived from any species, including human, mouse, or rabbit sources.
[0128] "Antibody fragments" include a portion of a full-length antibody, typically the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab') 2, and scFv fragments; diabodies; linear antibodies; fragments produced by Fab expression libraries, anti-idiotype (anti-Id) antibodies, CDRs (complementarity determining regions) and epitope binding fragments of any of the above (these fragments immunospecifically bind to cancer cell antigens, viral antigens or microbial antigens), single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
[0129] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, i.e., a single antibody, which includes other identical populations except for possible naturally occurring mutations (which may exist in small amounts). Monoclonal antibodies are highly specific, directed against a single antigenic site. In addition, in contrast to polyclonal antibody preparations (which include different antibodies directed against different determinants (epitopes)), each monoclonal antibody is directed against a single determinant on an antigen. In addition to their specificity, the advantage of monoclonal antibodies is that they can be synthesized without being contaminated by other antibodies. The modifier "monoclonal" represents that the feature of an antibody is obtained from a substantially homogeneous antibody population, and should not be construed as requiring the production of antibodies by any ad hoc method. For example, the monoclonal antibody used according to the present invention can be prepared by the hybridoma method described by Kohler et al. (1975) Nature [nature] 256:495, or can be prepared by a recombinant DNA method (referring to US 4816567). Monoclonal antibodies can be isolated from phage antibody libraries (using techniques described in Clackson et al. (1991) Nature, 352:624-628; Marks et al. (1991) J. Mol. Biol., 222:581-597) or from transgenic mice carrying a fully human immunoglobulin system (Lonberg (2008) Curr. Opinion 20(4):450-459).
[0130] The monoclonal antibodies herein specifically include chimeric antibodies, humanized antibodies and human antibodies.
[0131] Examples of cell binding agents include those described for use in WO 2007 / 085930, which is incorporated herein.
[0132] Tumor-associated antigens and cognate antibodies used in the embodiments of the present invention are listed below and described in more detail on pages 14 to 86 of WO 2017 / 186894 (incorporated herein).
[0133] (1) BMPR1B (bone morphogenetic protein receptor-IB type)
[0134] (2) E16 (LAT1, SLC7A5)
[0135] (3) STEAP1 (six-transmembrane prostatic epithelial antigen)
[0136] (4) 0772P (CA125, MUC16)
[0137] (5) MPF (MPF, MSLN, SMR, megakaryocyte promoting factor, mesothelin)
[0138] (6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b)
[0139] (7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, semaphorin 5b Hlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, semaphorin 5B)
[0140] (8) PSCA hlg (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene)
[0141] (9) ETBR (endothelin type B receptor)
[0142] (10) MSG783 (RNF124, hypothetical protein FLJ20315)
[0143] (11) STEAP2 (HGNC_8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer-associated gene 1, prostate cancer-associated protein 1, prostate six-transmembrane epithelial antigen 2, six-transmembrane prostate protein)
[0144] (12)TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel subfamily M member 4)
[0145] (13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratoma-derived growth factor)
[0146] (14) CD21 (CR2 (complement receptor 2) or C3DR (C3d / Epstein-Barr virus receptor) or Hs.73792)
[0147] (15) CD79b (CD79B, CD79β, IGb (immunoglobulin-related β), B29)
[0148] (16) FcRH2 (IFGP4, IRTA4, SPAP1A (phosphatase anchoring protein 1a containing SH2 domain), SPAP1B, SPAP1C)
[0149] (17) HER2 (ErbB2)
[0150] (18) NCA (CEACAM6)
[0151] (19)MDP(DPEP1)
[0152] (20)IL20R-α(IL20Ra, ZCYTOR7)
[0153] (21) Brevican (BCAN, BEHAB)
[0154] (22)EphB2R (DRT, ERK, Hek5, EPHT3, Tyro5)
[0155] (23)ASLG659(B7h)
[0156] (24) PSCA (prostate stem cell antigen precursor)
[0157] (25)GEDA
[0158] (26) BAFF-R (B cell activating factor receptor, BLyS receptor 3, BR3)
[0159] (27) CD22 (B cell receptor CD22-B isoform, BL-CAM, Lyb-8, Lyb8, SIGLEC-2, FLJ22814)
[0160] (27a)CD22 (CD22 molecule)
[0161] (28) CD79a (CD79A, CD79α), immunoglobulin-related α, a B cell-specific protein that covalently interacts with Igβ (CD79B) and forms a complex with Ig M molecules on the surface, transducing signals involved in B cell differentiation), pI: 4.84, MW: 25028TM: 2[P] gene chromosome: 19q13.2).
[0162] (29) CXCR5 (Burkitt lymphoma receptor 1, a G protein-coupled receptor activated by the CXCL13 chemokine, functions in lymphocyte migration and humoral defense, plays a role in HIV-2 infection and possibly the development of AIDS, lymphoma, myeloma, and leukemia); 372aa, pI: 8.54MW: 41959TM: 7[P] gene chromosome: 11q23.3,
[0163] (30) HLA-DOB (β subunit of MHC class II molecules (Ia antigens) that binds peptides and presents them to CD4+ T lymphocytes); 273aa, pI: 6.56, MW: 30820. TM: 1[P] gene chromosome: 6p21.3)
[0164] (31) P2X5 (Purinergic receptor P2X ligand-gated ion channel 5 (ion channel gated by extracellular ATP) may be involved in synaptic transmission and neurogenesis, and defects may contribute to the pathophysiology of idiopathic detrusor instability); 422aa), pI: 7.63, MW: 47206TM: 1[P] gene chromosome: 17p13.3).
[0165] (32) CD72 (B cell differentiation antigen CD72, Lyb-2); 359aa, pI: 8.66, MW: 40225, TM: 15[P] gene chromosome: 9p13.3).
[0166] (33) LY64 (lymphocyte antigen 64 (RP105), a type I membrane protein of the leucine-rich repeat (LRR) family, regulates B cell activation and apoptosis, and loss of function is associated with increased disease activity in patients with systemic lupus erythematosus); 661 aa, pI: 6.20, MW: 74147 TM: 1 [P] gene chromosome: 5q12).
[0167] (34) FcRH1 (Fc receptor-like protein 1 (putative receptor for the Fc domain of immunoglobulin, containing C2-type Ig-like domain and ITAM domain) may play a role in B lymphocyte differentiation); 429aa, pI: 5.28, MW: 46925TM: 1[P] gene chromosome: 1q21-1q22)
[0168] (35) IRTA2 (immunoglobulin superfamily receptor translocation-associated 2, a putative immune receptor that may play a role in B-cell development and lymphomagenesis; gene dysregulation caused by translocation occurs in some B-cell malignancies); 977aa, pI: 6.88, MW: 106468, TM: 1[P] gene chromosome: 1q21)
[0169] (36) TENB2 (TMEFF2, tomoregulin, TPEF, HPP1, TR, putative transmembrane proteoglycan, related to EGF / heregulin family growth factors and follistatin); 374aa)
[0170] (37) PSMA-FOLH1 (Folate hydrolase (prostate-specific membrane antigen) 1)
[0171] (38) SST (somatostatin receptor; note there are 5 subtypes)
[0172] (38.1) SSTR2 (somatostatin receptor 2)
[0173] (38.2) SSTR5 (somatostatin receptor 5)
[0174] (38.3)SSTR1
[0175] (38.4)SSTR3
[0176] (38.5)SSTR4
[0177] AvB6 - two subunits (39+40)
[0178] (39) ITGAV (integrin, αV)
[0179] (40) ITGB6 (integrin, β6)
[0180] (41) CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5)
[0181] (42) MET (met oncogene; hepatocyte growth factor receptor)
[0182] (43)MUC1 (mucin 1, cell surface associated)
[0183] (44) CA9 (Carbonic Anhydrase IX)
[0184] (45) EGFRvIII (epidermal growth factor receptor (EGFR), transcript variant 3,
[0185] (46)CD33 (CD33 molecule)
[0186] (47)CD19 (CD19 molecule)
[0187] (48) IL2RA (interleukin 2 receptor, α); NCBI reference sequence: NM_000417.2);
[0188] (49) AXL (AXL receptor tyrosine kinase)
[0189] (50) CD30-TNFRSF8 (tumor necrosis factor receptor superfamily member 8)
[0190] (51) BCMA (B cell maturation antigen)-TNFRSF17 (tumor necrosis factor receptor superfamily member 17)
[0191] (52) CT Ags-CTA (cancer testis antigen)
[0192] (53) CD174 (Lewis Y)-FUT3 (fucosyltransferase 3 (galactoside 3 (4)-L-fucosyltransferase, Lewis blood type)
[0193] (54) CLEC14A (C-type lectin domain family 14 member A; Genbank accession number NM175060)
[0194] (55) GRP78-HSPA5 (heat shock 70 kDa protein 5 (glucose regulated protein, 78 kDa)
[0195] (56)CD70 (CD70 molecule) L08096
[0196] (57) Stem cell specific antigens. For example:
[0197] 5T4 (see entry (63) below)
[0198] CD25 (see above item (48))
[0199] CD32
[0200] LGR5 / GPR49
[0201] ·Prominin / CD133
[0202] (58)ASG-5
[0203] (59) ENPP3 (ectonucleotide pyrophosphatase / phosphodiesterase 3)
[0204] (60) PRR4 (proline rich 4 (tears))
[0205] (61) GCC-GUCY2C (Guanylate cyclase 2C (heat-stable enterotoxin receptor)
[0206] (62) Liv-1-SLC39A6 (solute carrier family 39 (zinc transporter) member 6)
[0207] (63) 5T4, trophoblast glycoprotein, TPBG-TPBG (trophoblast glycoprotein)
[0208] (64) CD56-NCMA1 (neural cell adhesion molecule 1)
[0209] (65) CanAg (tumor-associated antigen CA242)
[0210] (66) FOLR1 (Folic acid receptor 1)
[0211] (67) GPNMB (glycoprotein (transmembrane) nmb)
[0212] (68) TIM-1-HAVCR1 (Hepatitis A virus cellular receptor 1)
[0213] (69) RG-1 / Prostate tumor target Mindin-Mindin / RG-1
[0214] (70) B7-H4-VTCN1 (T cell activation inhibitor 1 containing V-set domain)
[0215] (71) PTK7 (PTK7 protein tyrosine kinase 7)
[0216] (72)CD37 (CD37 molecule)
[0217] (73)CD138-SDC1 (syndecan 1)
[0218] (74) CD74 (CD74 molecule, major histocompatibility complex, class II invariant chain)
[0219] (75) Tight junction protein - CL (tight junction protein)
[0220] (76) EGFR (epidermal growth factor receptor)
[0221] (77) Her3 (ErbB3) - ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (bird))
[0222] (78)RON-MST1R (macrophage stimulatory 1 receptor (c-met-related tyrosine kinase))
[0223] (79) EPHA2 (EPH receptor A2)
[0224] (80) CD20-MS4A1 (transmembrane 4-domain subfamily A member 1)
[0225] (81) Tenascin C-TNC
[0226] (82) FAP (Fibroblast Activation Protein α)
[0227] (83) DKK-1 (Dickkopf 1 homolog (Xenopus laevis))
[0228] (84)CD52 (CD52 molecule)
[0229] (85) CS1-SLAMF7 (SLAM family member 7)
[0230] (86) Endoglin-ENG (Endoglin)
[0231] (87) Annexin A1-ANXA1 (Annexin A1)
[0232] (88) V-CAM (CD106) - VCAM1 (vascular cell adhesion molecule 1)
[0233] Additional tumor-associated antigens and cognate antibodies of interest are:
[0234] (89)ASCT2 (ASC transporter 2, also known as SLC1A5).
[0235] ASCT2 antibodies are described in WO 2018 / 089393 (incorporated herein by reference).
[0236] The cell binding agent can be labeled, for example, before incorporation as a conjugate or as part of a conjugate to aid in detection or purification of the agent. The label can be a biotin label. In another embodiment, the cell binding agent can be labeled with a radioactive isotope.
[0237] Treatment
[0238] The conjugates of the present invention can be used in a method of treatment. A method of treatment is also provided, comprising administering a therapeutically effective amount of a conjugate of Formula IV to a subject in need of treatment. The term "therapeutically effective amount" is an amount sufficient to show a benefit to the patient. Such a benefit may be at least alleviation of at least one symptom. The actual amount administered and the rate and time course of administration will depend on the nature and severity of the disease being treated. Prescription of treatment (e.g., determination of dosage) is the responsibility of general practitioners and other physicians.
[0239] Depending on the condition to be treated, the conjugates may be administered alone or in combination with other treatments, either simultaneously or sequentially. Examples of treatments and therapies include, but are not limited to, chemotherapy (including administration of active agents such as drugs); surgery; and radiation therapy.
[0240] Therefore, the pharmaceutical composition according to the present invention and for use according to the present invention may also contain, in addition to the active ingredient (i.e., the conjugate of formula IV), a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. These materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The exact nature of the carrier or other material will depend on the route of administration, which may be oral or by injection, such as skin, subcutaneous or intravenous.
[0241] Pharmaceutical compositions for oral administration can be in tablet, capsule, powder or liquid form. Tablets can include solid carriers or adjuvants. Liquid pharmaceutical compositions generally include liquid carriers, such as water, petroleum, animal or vegetable oils, mineral oils or synthetic oils. Physiological saline solutions, dextrose or other sugar solutions or glycols, such as ethylene glycol, propylene glycol or polyethylene glycol can be included. Capsules can include solid carriers, such as gelatin.
[0242] For intravenous, cutaneous or subcutaneous injections, or injections at the site of pain, the active ingredient will be in the form of an acceptable aqueous solution for parenteral administration, which is pyrogen-free and has a suitable pH, isotonicity and stability. Those skilled in the art are fully capable of using, for example, isotonic vehicles, such as sodium chloride injection, Ringer's injection, lactated Ringer's injection to prepare suitable solutions. When necessary, preservatives, stabilizers, buffers, antioxidants and / or other additives may be included.
[0243] The conjugates may be used to treat proliferative and autoimmune diseases.The term "proliferative disease" relates to unwanted or uncontrolled cell proliferation of excessive or abnormal cells, whether in vitro or in vivo, which is undesirable, such as neoplastic or hyperplastic growth.
[0244] Examples of proliferative disorders include, but are not limited to, benign, precancerous and malignant cell proliferations, including, but not limited to, neoplasms and tumors (e.g., histiocytomas, gliomas, astrocytomas, osteomas), cancers (e.g., lung cancer, small cell lung cancer, gastrointestinal cancer, intestinal cancer, colon cancer, breast cancer, ovarian cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, sarcomas, osteosarcomas, Kaposi's sarcoma, melanoma), leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g., disorders of connective tissue), and atherosclerosis. Other cancers of interest include, but are not limited to, hematological malignancies, such as leukemias and lymphomas, such as non-Hodgkin lymphomas and subtypes (e.g., DLBCL, marginal zone lymphomas, mantle zone lymphomas, and follicular lymphomas), Hodgkin lymphomas, AML, and other cancers of B or T cell origin. Any cell type can be treated including, but not limited to, lung, gastrointestinal tract (e.g., including intestine, colon), breast (breast or mammary), ovary, prostate, liver (liver or hepatic), kidney (kidney or renal), bladder, pancreas, brain and skin.
[0245] Examples of autoimmune diseases include the following: rheumatoid arthritis, autoimmune demyelinating diseases (e.g., multiple sclerosis, allergic encephalomyelitis), psoriatic arthritis, endocrine eye diseases, uveoretinitis, systemic lupus erythematosus, myasthenia gravis, Graves' disease, glomerulonephritis, autoimmune liver disorders, inflammatory bowel diseases (e.g., Crohn's disease), allergies, anaphylaxis, Sjögren's syndrome ( syndrome), type 1 diabetes, primary biliary cirrhosis, Wegener's granulomatosis, fibromyalgia, polymyositis, dermatomyositis, multiple endocrine failure, Schmidt's syndrome, autoimmune uveitis, Addison's disease, adrenalitis, thyroiditis, Hashimoto's thyroiditis, autoimmune thyroid disease, pernicious anemia, gastric atrophy, chronic hepatitis, lupus hepatitis, atherosclerosis, subacute cutaneous lupus erythematosus, hypoparathyroidism, Dressler's syndrome syndrome), autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, pemphigus vulgaris, pemphigus, dermatitis herpetiformis, alopecia areata, pemphigoid, scleroderma, progressive systemic sclerosis, CREST syndrome (calcification, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia), male and female autoimmune infertility, ankylosing spondylitis, ulcerative colitis, mixed connective tissue disease, polyarteritis nodosa, systemic necrotizing vasculitis, atopic dermatitis, atopic rhinitis, Goodpasture's syndrome syndrome), Chagas' disease, sarcoidosis, rheumatic fever, asthma, recurrent miscarriage, antiphospholipid syndrome, farmer's lung, erythema multiforme, postcardiotomy syndrome, Cushing's syndrome, autoimmune chronic active hepatitis, bird farmer's lung, toxic epidermal necrolysis, Alport's syndrome, alveolitis, allergic alveolitis, fibrosing alveolitis, interstitial lung disease, erythema nodosum, pyoderma gangrenosum, transfusion reaction, Takayasu's arteritis, polymyalgia rheumatica, temporal arteritis, schistosomiasis, giant cell arteritis, ascariasis, aspergillosis, Sampter's syndrome, eczema, lymphomatoid granulomatosis, Behcet's disease, Caplan's syndrome syndrome), Kawasaki's disease, dengue fever, encephalomyelitis, endocarditis, endomyocardial fibrosis, endophthalmitis, erythema elevatum et diutinum, psoriasis, erythroblastosis fetalis, eosinophilic fasciitis, Shulman's syndrome, Felty's syndromesyndrome), filariasis, cyclitis, chronic cyclitis, metachronous cyclitis, Fuch's cyclitis, IgA nephropathy, Henoch-Schonlein purpura, graft-versus-host disease, transplant rejection, cardiomyopathy, myasthenic syndrome (Eaton-Lambert syndrome), relapsing polychondritis, cryoglobulinemia, Waldenstrom's macroglobulemia, Evan's syndrome, and autoimmune gonadal failure.
[0246] In some embodiments, the autoimmune disease is a disorder of B lymphocytes (e.g., systemic lupus erythematosus, Goodpasture's syndrome, rheumatoid arthritis, and type I diabetes), Th1-lymphocytes (e.g., rheumatoid arthritis, multiple sclerosis, psoriasis, Sjögren's syndrome, Hashimoto's thyroiditis, Graves' disease, primary biliary cirrhosis, Wegener's granulomatosis, tuberculosis, or graft-versus-host disease), or Th2 lymphocytes (e.g., atopic dermatitis, systemic lupus erythematosus, atopic asthma, rhinoconjunctivitis, allergic rhinitis, Omenn's syndrome, or chronic graft-versus-host disease). Typically, disorders involving dendritic cells involve disorders of Th1 lymphocytes or Th2 lymphocytes. In some embodiments, the autoimmune disorder is a T cell-mediated immunological disorder.
[0247] "Chemotherapeutic agents" are chemical compounds useful in the treatment of cancer, regardless of their mechanism of action. Classes of chemotherapeutic agents include, but are not limited to, alkylating agents, antimetabolites, spindle poison plantalkaloids, cytotoxic / antitumor antibiotics, topoisomerase inhibitors, antibodies, photosensitizers, and kinase inhibitors. Chemotherapeutic agents include compounds used in "targeted therapies" and conventional chemotherapy.
[0248] Examples of chemotherapeutic agents include: Erlotinib ( Genentech / OSI Pharmaceuticals (OSI Pharm.), docetaxel ( Sanofi-Aventis Group (Sanofi-Aventis), 5-FU (fluorouracil, 5-fluorouracil, CAS No. 51-21-8), gemcitabine ( Eli Lilly (Lilly), PD-0325901 (CAS No. 391210-10-9, Pfizer), cisplatin (cis-diamine, dichloroplatinum (II), CAS No. 15663-27-1), carboplatin (CAS No. 41575-94-4), paclitaxel ( Bristol-Myers Squibb Oncology (Princeton, NJ), trastuzumab ( Genentech), temozolomide (4-methyl-5-oxo-2,3,4,6,8-pentaazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide, CAS No. 85622-93-1, Schering Plough), tamoxifen ((Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethylamine, ), and doxorubicin Akti-1 / 2, HPPD, and rapamycin.
[0249] Further examples of chemotherapeutic agents include: oxaliplatin ( Sanofi Group), bortezomib ( Millennium Pharm.), Sutent ( SU11248, Pfizer), letrozole ( Novartis), imatinib mesylate ( Novartis), XL-518 (Mek inhibitor, Exelixis, WO 2007 / 044515), ARRY-886 (Mek inhibitor, AZD6244, Array BioPharma, AstraZeneca), SF-1126 (PI3K inhibitor, Semafore Pharmaceuticals), BEZ-235 (PI3K inhibitor, Novartis), XL-147 (PI3K inhibitor, Exelixis), PTK787 / ZK 222584 (Novartis), fulvestrant ( AstraZeneca), leucovorin or folinic acid, rapamycin (sirolimus, Wyeth), lapatinib ( GSK572016, Glaxo Smith Kline), lonafarnib (SARASAR TM , SCH 66336, Schering-Plough Corporation), sorafenib ( BAY43-9006, Bayer Labs), gefitinib ( AstraZeneca), irinotecan ( CPT-11, Pfizer), tipifarnib (ZARNESTRA TM , Johnson & Johnson), ABRAXANE TM (without Cremophor), an albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Skåneburg, IL), vandetanib (rINN, ZD6474, AstraZeneca), chloranmbucil, AG1478, AG1571 (SU 5271; Sugen), temsirolimus ( Wyeth), pazopanib (GSK), canfosfamide ( Telik, thiotepa, and cyclosphosphamide Alkyl sulfonates, such as busulfan, improsulfan, and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimine and methylamelamine, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylomelamine; acetogenins (particularly bullatacin and bullatacinone); camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its synthetic analogues adozelesin, carzelesin and bizelesin); cryptophycin (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin;Nitrogen mustards, such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, hydrochloride), melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracilmustard; nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics, such as enediyne antibiotics (e.g., calicheamicin, calicheamicin gamma 1I, calicheamicin omega 1I (Angewandte), ... Chem. Intl. Ed. Engl. (1994) 33: 183-186); dynemicin, dynemicin A; bisphosphonates, such as clodronate; esperamicin;and new tumor suppressor protein chromophores and related colored proteins (enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, ditoxin detorubicin, 6-diazo-5-oxo-L-norleucine, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolo-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, nemorubicin, marcellomycin, mitomycins (e.g., mitomycin C), mycophenolic acid ( acid, nogalamycin, olivomycin, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin n); antimetabolites, such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs, such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs, such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs, such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens, such as caprotestosterone, drostanolone propionate, cyclothiodine, melastane, testolactone; antiadreners, such as aminoglutethimide, mitotane, trilostane;Folic acid supplements, such as frolinic acid, aceglucuronide, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatraxate, defosfamide, demecolcine, diaziquone, elfornithine, and elliptinium acetate acetate; epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids, such as maytansine and ansamitocin; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; Polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (particularly T-2 toxin, verracurin A, roridin A, and roridin B) A) and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs, such as cisplatin and carboplatin; vinblastine; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine Mitoxantrone (novantrone); teniposide (teniposide); edatrexate (edatrexate); daunomycin (daunomycin); aminopterin; capecitabine ( Roche); ibandronate; CPT-11; topoisomerase inhibitor RFS2000; difluoromethylornithine (DMFO); retinoic acid, such as retinoic acid; and any pharmaceutically acceptable salts, acids and derivatives thereof.
[0250] Also included within the definition of "chemotherapeutic agent" are: (i) antihormonal agents that act to modulate or inhibit the effects of hormones on tumors, such as antiestrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including tamoxifen citrate), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and (toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production by the adrenal glands, such as 4(5)-imidazoles, aminoglutethimide, (megestrol acetate), (exemestane; Pfizer), formestanie, fadrozole, (vorozole), (letrozole; Novartis), and (anastrozole; AstraZeneca; (iii) antiandrogens, such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and troxacitabine (1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase inhibitors, such as MEK inhibitors (WO 2007 / 044515); (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, particularly oligonucleotides that inhibit the expression of genes in signal transduction pathways associated with abnormal cell proliferation, such as PKC-α, Raf and H-Ras, such as oblimersen ( Genta Inc.); (vii) ribozymes, such as VEGF expression inhibitors (e.g. ) and HER2 expression inhibitors; (viii) vaccines, such as gene therapy vaccines, e.g. and rIL-2; topoisomerase 1 inhibitors, e.g. rmRH; (ix) anti-angiogenic agents, such as bevacizumab ( Genentech Inc.); and any pharmaceutically acceptable salts, acids and derivatives of the foregoing.
[0251] Also included in the definition of "chemotherapeutic agent" are therapeutic antibodies, such as alemtuzumab (Campath), bevacizumab ( Genentech Inc.); cetuximab ( Imclone); panitumumab ( Amgen), rituximab ( Genentech / Biogen Idec), pertuzumab (OMNITARG TM , 2C4, Genentech), trastuzumab ( Genentech), tositumomab (Bexxar, Corixia), and antibody-drug conjugates, gemtuzumab ( Wyeth).
[0252] Humanized monoclonal antibodies with therapeutic potential as chemotherapeutic agents for combination with the conjugates of the invention include: alemtuzumab, apolizumab, aselizumab, atlizumab, bapineuzumab, bevacizumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol), cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab ozogamicin, inotuzumabozogamicin), ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab, ocrelizumab, omalizumab, palivizumab, pascolizumab pascolizumab, pecfusituzumab, pectuzumab, pertuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan, tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab, trastuzumab, tucotuzumab celmoleukin, tucusituzumab, umavizumab, urtoxazumab, and visilizumab.
[0253] Preparations
[0254] While it is possible for the conjugate to be used (eg, administered) alone, it is often preferable to present it as a composition or formulation.
[0255] In one embodiment, the composition is a pharmaceutical composition (eg, formulation, preparation, medicament) comprising a conjugate described herein and a pharmaceutically acceptable carrier, diluent, or excipient.
[0256] In one embodiment, the composition is a pharmaceutical composition comprising at least one conjugate described herein and one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including but not limited to pharmaceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, antioxidants, lubricants, stabilizers, solubilizers, surfactants (e.g., wetting agents), masking agents, colorants, flavoring agents, and sweeteners.
[0257] In one embodiment, the composition further comprises other active agents, such as other therapeutic or prophylactic agents.
[0258] Suitable carriers, diluents, excipients, etc. can be found in the standard pharmaceutical literature. See, e.g., Handbook of Pharmaceutical Additives [Handbook of Pharmaceutical Additives], 2nd edition (M.Ash and I.Ash eds.), 2001 (Synapse Information Resources, Inc., Endicott, New York, USA), Remington's Pharmaceutical Sciences Remington's Pharmaceutical Sciences, 20th edition, Lippincott, Williams & Wilkins, 2000; and Handbook of Pharmaceutical Excipients [Handbook of Pharmaceutical Excipients], 2nd edition, 1994.
[0259] Another aspect of the present invention relates to a method for preparing a pharmaceutical composition, the method comprising the step of: 11 The radiolabeled conjugate or conjugate-like compound is mixed with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art (e.g., carriers, diluents, excipients, etc.). If formulated as discrete units (e.g., tablets, etc.), each unit contains a predetermined amount (dose) of the active compound.
[0260] As used herein, the term "pharmaceutically acceptable" relates to compounds, ingredients, materials, compositions, dosage forms, etc., which are suitable, within the scope of sound medical judgment, for contact with the tissues of the subject (e.g., human) in question, without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio. Each carrier, diluent, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.
[0261] The formulation can be prepared by any method well known in the pharmaceutical field. Such a method includes the step of associating the active compound with a carrier constituting one or more auxiliary ingredients. Generally, the formulation is prepared by uniformly and closely associating the active compound with a carrier (e.g., a liquid carrier, a finely divided solid carrier, etc.), and then shaping the product as required.
[0262] The formulations may be prepared to provide fast or slow release; immediate, delayed, timed or sustained release; or a combination thereof.
[0263] Preparations suitable for parenteral administration (e.g., by injection) include aqueous or non-aqueous, isotonic, pyrogen-free sterile liquids (e.g., solutions, suspensions) in which the active ingredient is dissolved, suspended, or otherwise provided (e.g., in liposomes or other particulates). Such liquids may additionally contain other pharmaceutically acceptable ingredients, such as antioxidants, buffers, preservatives, stabilizers, antibacterial agents, suspending agents, thickeners, and solutes, which can make the preparation isotonic with the blood (or other relevant body fluids) of the intended recipient. Examples of excipients include, for example, water, alcohols, polyols, glycerol, vegetable oils, etc. Examples of suitable isotonic carriers for such preparations include sodium chloride injection, Ringer's solution, or lactated Ringer's injection. Typically, the concentration of the active ingredient in the liquid is from about 1 ng / ml to about 10 μg / ml, for example, from about 10 ng / ml to about 1 μg / ml. The formulation can be present in unit dose or multi-dose sealed containers (e.g., ampoules and vials), and can be stored in freeze-dried (lyophilized) conditions, requiring only the addition of a sterile liquid carrier (e.g., water) for injection prior to use (immediately). Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets.
[0264] dose
[0265] Those skilled in the art will recognize that the appropriate dosage of the conjugate, and the composition comprising the conjugate, may vary from patient to patient. Determining the optimal dosage will generally involve a balance between the level of therapeutic beneficial effects and any risks or harmful side effects. The selected dosage level will depend on a variety of factors, including but not limited to the activity of the specific compound, the route of administration, the time of administration, the excretion rate of the compound, the duration of treatment, other drugs, compounds and / or materials used in combination, the severity of the condition, and the race, sex, age, weight, condition, overall health and previous medical history of the patient. The amount of the compound and the route of administration will ultimately be determined by the physician, veterinarian or clinician, although the dosage will generally be selected to achieve a local concentration at the site of action to achieve the desired effect without causing substantial harmful or toxic side effects.
[0266] Can be administered continuously or intermittently (e.g., divided doses at appropriate intervals) at one dose throughout the treatment process. Methods for determining the most effective mode of administration and dosage are well known to those skilled in the art and will vary depending on the formulation used for treatment, the purpose of treatment, the one or more target cells treated, and the subject treated. Single or multiple administrations can be performed at dosage levels and patterns selected by the treating physician, veterinarian, or clinician.
[0267] Typically, a suitable dose of the active compound is in the range of about 100 ng to about 25 mg per kilogram of subject body weight per day (more typically about 1 μg to about 10 mg). When the active compound is a salt, ester, amide, prodrug, etc., the amount of administration is calculated based on the parent compound, so the actual weight to be used is increased proportionally.
[0268] The above dosages may apply to the conjugate, or to an effective amount of the compound that is releasable upon cleavage of the linker.
[0269] For the prevention or treatment of disease, the appropriate dose of the ADC of the present invention will depend on the type of disease to be treated, the severity and course of the disease, whether the molecule is administered for prevention or treatment purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician, as defined above. The molecule can be appropriately administered to the patient at one time or through a series of treatments. Depending on the type and severity of the disease, molecules of about 1 μg / kg to 100 mg / kg or more are initial candidate doses for administration to the patient, for example, by one or more separate administrations or continuous infusions. For repeated administrations of several days or longer, depending on the condition, treatment is continued until the desired containment of disease symptoms occurs. Other dosage regimens may be useful. The progress of the therapy is easily monitored by conventional techniques and assays.
[0270] Drug loading
[0271] Drug loading (p) is the average amount of drug per ligand unit, which can be a cell binding agent, such as an antibody.
[0272] The average drug quantity per antibody in the ADC preparation from the conjugation reaction can be characterized by conventional means, such as UV, reverse phase HPLC, HIC, mass spectrometry, ELISA assay and electrophoresis. The quantitative distribution of ADCs according to p can also be determined. By ELISA, the average value of p in a specific ADC preparation can be determined (Hamblett et al. (2004) Clin. Cancer Res. [Clinical Cancer Research] 10: 7063-7070; Sanderson et al. (2005) Clin. Cancer Res. [Clinical Cancer Research] 11: 843-852). However, the distribution of p (drug) values cannot be distinguished by antibody-antigen binding and detection limits of ELISA. Moreover, the ELISA assay for detecting antibody-drug conjugates cannot determine where the drug portion is attached to the antibody, such as a heavy chain or light chain fragment or a specific amino acid residue. In some cases, the separation, purification and characterization of homogeneous ADCs can be achieved by methods such as reverse phase HPLC or electrophoresis, where p is a certain value of ADCs from other drug loads. Such techniques are also applicable to other types of conjugates.
[0273] For some antibody-drug conjugates, p may be limited by the number of attachment sites on the antibody. For example, an antibody may have only one or a few cysteine thiol groups, or may have only one or a few sufficiently reactive thiol groups through which a linker may be attached. Higher drug loading may result in aggregation, insolubility, toxicity, or loss of cell permeability of certain antibody-drug conjugates.
[0274] Typically, during the conjugation reaction, less than the theoretical maximum drug moiety is conjugated to the antibody. Antibodies may contain, for example, many lysine residues that do not react with drug linkers. Only the most reactive lysine groups can react with amine-reactive linker reagents. Moreover, only the most reactive cysteine thiol groups can react with thiol-reactive linker reagents. Typically, antibodies do not contain many (if any) free and reactive cysteine thiol groups that can be attached to drug moieties. Most cysteine thiol residues in antibodies of the compound exist in the form of disulfide bridges and must be reduced with a reducing agent (such as dithiothreitol (DTT) or TCEP) under partial or full reducing conditions. The loading (drug / antibody ratio) of the ADC can be controlled in several different ways, including: (i) limiting the molar excess of the drug linker relative to the antibody; (ii) limiting the conjugation reaction time or temperature; and (iii) partial or limiting reducing conditions for cysteine thiol modification.
[0275] Some antibodies have reducible interchain disulfide bonds, i.e., cysteine bridges. By treating with a reducing agent such as DTT (dithiothreitol), antibodies can be made reactive to be conjugated with linker reagents. Therefore, each cysteine bridge will theoretically form two reactive thiol nucleophiles. By reacting lysine with 2-iminothiolane (Traut's reagent), additional nucleophilic groups can be introduced into antibodies, resulting in amines being converted into thiols. Reactive thiol groups can be introduced into antibodies (or fragments thereof) by engineering one, two, three, four or more cysteine residues (e.g., preparing mutant antibodies comprising one or more non-natural cysteine amino acid residues). US 7521541 teaches engineering antibodies by introducing reactive cysteine amino acids.
[0276] Cysteine amino acids can be engineered at reactive sites of antibodies and do not form intrachain or intermolecular disulfide bonds (Junutula, et al., 2008b Nature Biotech., 26(8):925-932; Dornan et al. (2009) Blood 114(13):2721-2729; US 7521541; US 7723485; WO 2009 / 052249). Engineered cysteine thiols can react with drug linkers of the present invention (i.e., compounds of Formula I) having thiol-reactive electrophilic groups such as maleimide or α-haloamide to form ADCs with cysteine engineered antibodies. Thus, the position of the drug unit can be designed, controlled, and known. Since engineered cysteine thiol groups typically react with drug linker reagents in high yield, drug loading can be controlled. IgG antibodies were engineered to introduce a cysteine amino acid by substitution at a single site on either the heavy or light chain, giving two new cysteines on a symmetric antibody. Drug loadings approaching 2 could be achieved, with the conjugate product ADC approaching homogeneity.
[0277] If more than one nucleophilic or electrophilic group of an antibody reacts with a drug linker, the resulting product may be a mixture of ADC compounds, wherein the drug units attached to the antibody are distributed as, for example, 1, 2, 3, etc. Liquid chromatography methods such as polymer reverse phase (PLRP) and hydrophobic interaction (HIC) can separate the compounds in the mixture by drug loading value. Preparations of ADCs with a single drug loading value (p) can be separated, however, these single loading value ADCs may still be a heterogeneous mixture because the drug units can be attached to different sites on the antibody via the linker.
[0278] Thus, the antibody-drug conjugate compositions of the invention may include mixtures of antibody-drug conjugates, wherein the antibody bears one or more drug moieties, and wherein the drug moieties may be attached to the antibody at various amino acid residues.
[0279] In one embodiment, the average number of drugs per cell-binding agent is in the range of 1 to 20. In some embodiments, the range is selected from 1 to 10, 2 to 10, 2 to 8, 2 to 6, and 4 to 10.
[0280] In some embodiments, there is one drug per cell-binding agent.
[0281] General synthetic route
[0282] A compound having formula I (wherein R L Having formula Ia) can
[0283]
[0284] By connecting a compound having Formula 3:
[0285]
[0286] or an activated version thereof, from a compound having formula 2 (wherein R L* It is synthesized by -QH).
[0287] Such reactions can be carried out under amide coupling conditions.
[0288] The compound having formula 2 can be prepared by a compound having formula 4:
[0289]
[0290] (where R L*prot Yes-Q-Prot N , where Prot N is an amine protecting group).
[0291] The compound having formula 4 can be prepared by a compound having formula 5:
[0292]
[0293] The coupling with compound A3 was synthesized using Friedlander reaction.
[0294] The compound of formula 5 can be prepared from the compound of formula 6:
[0295]
[0296] Synthesized by removal of the trifluoroacetamide protecting group.
[0297] The compound of formula 6 can be synthesized by coupling: R L*prot -OH to compound I7.
[0298] A compound having formula I (wherein R L having formula Ia or Ib) can be obtained from compound I11 via compound R L -OH or its activated form is coupled to form.
[0299] Amine Protecting Groups
[0300] Amine protecting groups are well known to those skilled in the art. Reference is made in particular to Greene's Protecting Groups in Organic Synthesis, 4th edition, John Wiley & Sons, 2007 (ISBN 978-0-471-69754-1), pp. 696-871 for disclosure of suitable protecting groups.
[0301] Further preferences
[0302] The following preferences may apply to all aspects of the invention as described above, or may relate to a single aspect. These preferences may be combined together in any combination.
[0303] Q X
[0304] In one embodiment, Q is an amino acid residue. The amino acid can be a natural amino acid or an unnatural amino acid.
[0305] In one embodiment, Q is selected from the group consisting of: Phe, Lys, Val, Ala, Cit, Leu, He, Arg, and Trp, wherein Cit is citrulline.
[0306] In one embodiment, Q comprises a dipeptide residue. The amino acids in the dipeptide can be any combination of natural amino acids and non-natural amino acids. In certain embodiments, the dipeptide comprises natural amino acids. When the linker is a cathepsin unstable linker, the dipeptide is the action site of cathepsin-mediated cleavage. Then, the dipeptide is the recognition site of cathepsin.
[0307] In one embodiment, Q is selected from:
[0308] NH -Phe-Lys- C=O ,
[0309] NH -Val-Ala-C=O ,
[0310] NH -Val-Lys- C=O ,
[0311] NH -Ala-Lys- C=O ,
[0312] NH -Val-Cit- C=O ,
[0313] NH -Phe-Cit- C=O ,
[0314] NH -Leu-Cit- C=O ,
[0315] NH -Ile-Cit- C=O ,
[0316] NH -Phe-Arg- C=O ,
[0317] NH -Trp-Cit- C=O ,and
[0318] NH -Gly-Val- C=O ;
[0319] Where Cit is citrulline.
[0320] Preferably, Q is selected from:
[0321] NH -Phe-Lys- C=O ,
[0322] NH -Val-Ala- C=O ,
[0323] NH -Val-Lys- C=O ,
[0324] NH -Ala-Lys- C=O ,and
[0325] NH -Val-Cit- C=O .
[0326] Most preferably, Q is selected from NH-Phe-Lys- C=O , NH -Val-Cit- C=O or NH -Val-Ala- C=O .
[0327] Other dipeptide combinations of interest include:
[0328] NH -Gly-Gly- C=O ,
[0329] NH -Gly-Val- C=O
[0330] NH -Pro-Pro- C=O ,and
[0331] NH -Val-Glu- C=O .
[0332] Other dipeptide combinations may be used, including those described by Dubowchik et al., Bioconjugate Chemistry, 2002, 13, 855-869, which is incorporated herein by reference.
[0333] In some embodiments, Q is a tripeptide residue. The amino acids in the tripeptide can be any combination of natural amino acids and non-natural amino acids. In some embodiments, the tripeptide comprises natural amino acids. When the linker is a cathepsin labile linker, the tripeptide is the action site of cathepsin-mediated cleavage. Then, the tripeptide is the recognition site of cathepsin. Particularly interesting tripeptide linkers are:
[0334] NH -Glu-Val-Ala- C=O
[0335] NH -Glu-Val-Cit- C=O
[0336] NH -αGlu-Val-Ala- C=O
[0337] NH -αGlu-Val-Cit- C=O
[0338] In some embodiments, Q is a tetrapeptide residue. The amino acids in the tetrapeptide can be any combination of natural amino acids and non-natural amino acids. In some embodiments, the tetrapeptide comprises natural amino acids. When the linker is a cathepsin labile linker, the tetrapeptide is the site of action for cathepsin-mediated cleavage. Then, the tetrapeptide is the recognition site for cathepsin. The tetrapeptide linkers of particular interest are:
[0339] NH -Gly-Gly-Phe-Gly C=O ;and
[0340] NH -Gly-Phe-Gly-Gly C=O .
[0341] In some embodiments, the tetrapeptide is:
[0342] NH -Gly-Gly-Phe-Gly C=O .
[0343] In the above representation of peptide residues, NH - indicates the N-terminus of the residue, and - C=O represents the C-terminus of the residue. The C-terminus is bound to the NH of A*.
[0344] Glu represents the residue of glutamic acid, that is:
[0345]
[0346] αGlu represents the residue of glutamic acid when bound via the α chain, i.e.:
[0347]
[0348] In one embodiment, in appropriate cases, the amino acid side chains are chemically protected. The side chain protecting group can be a group as discussed above. The protected amino acid sequence can be cleaved by enzymes. For example, a dipeptide sequence comprising a Lys residue protected by a Boc side chain can be cleaved by cathepsin.
[0349] Protecting groups for amino acid side chains are well known in the art and are described in the Novabiochem catalog and as described above.
[0350] G L
[0351] G L Can be selected from
[0352]
[0353]
[0354] Where Ar represents C 5-6 an arylene group, such as phenylene, and X represents C 1-4 alkyl.
[0355] In some embodiments, G L Selected from G L1-1 and G L1-2 In some of these embodiments, G L It's G L1-1 .
[0356] G LL
[0357] G LL Can be selected from:
[0358]
[0359]
[0360] Where Ar represents C 5-6 an arylene group, such as phenylene, and X represents C 1-4 alkyl.
[0361] In some embodiments, G LL Selected from G LL1-1 and G LL1-2 In some of these embodiments, G LL It's G LL1-1 .
[0362] X
[0363] X is:
[0364]
[0365] Wherein a=0 to 5, b1=0 to 16, b2=0 to 16, c=0 or 1, d=0 to 5, wherein at least b1 or b2=0 and at least c1 or c2=0.
[0366] a can be 0, 1, 2, 3, 4, or 5. In some embodiments, a is 0 to 3. In some of these embodiments, a is 0 or 1. In other embodiments, a is 0.
[0367] b1 can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16. In some embodiments, b1 is 0 to 12. In some of these embodiments, b1 is 0 to 8, and can be 0, 2, 3, 4, 5, or 8.
[0368] b2 can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16. In some embodiments, b2 is 0 to 12. In some of these embodiments, b2 is 0 to 8, and can be 0, 2, 3, 4, 5, or 8.
[0369] Only one of b1 and b2 can be non-zero.
[0370] c1 can be 0 or 1.
[0371] c2 can be 0 or 1.
[0372] Only one of c1 and c2 can be non-zero.
[0373] d can be 0, 1, 2, 3, 4, or 5. In some embodiments, d is 0 to 3. In some of these embodiments, d is 1 or 2. In further embodiments, d is 2. In further embodiments, d is 5.
[0374] In some embodiments of X, a is 0, b1 is 0, c1 is 1, c2 is 0 and d is 2, and b2 can be from 0 to 8. In some of these embodiments, b2 is 0, 2, 3, 4, 5, or 8.
[0375] In some embodiments of X, a is 1, b2 is 0, c1 is 0, c2 is 0 and d is 0, and b1 can be from 0 to 8. In some of these embodiments, b1 is 0, 2, 3, 4, 5 or 8.
[0376] In some embodiments of X, a is 0, b1 is 0, c1 is 0, c2 is 0 and d is 1, and b2 can be from 0 to 8. In some of these embodiments, b2 is 0, 2, 3, 4, 5, or 8.
[0377] In some embodiments of X, b1 is 0, b2 is 0, c1 is 0, c2 is 0 and one of a and d is 0. The other of a and d is from 1 to 5. In some of these embodiments, the other of a and d is 1. In other of these embodiments, the other of a and d is 5.
[0378] In some embodiments of X, a is 1, b2 is 0, c1 is 0, c2 is 1, d is 2, and b1 can be from 0 to 8. In some of these embodiments, b2 is 0, 2, 3, 4, 5, or 8.
[0379] In some embodiments, R L Has formula Ib.
[0380] In some embodiments, R LL It has the formula Ib'.
[0381] RL1 and R L2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropene group or a cyclobutene group.
[0382] In some embodiments, R L1 and R L2 Both are H.
[0383] In some embodiments, R L1 is H and R L2 It's methyl.
[0384] In some embodiments, R L1 and R L2 Both are methyl groups.
[0385] In some embodiments, R L1 and R L2 Together with the carbon atom to which they are bonded they form a cyclopropene group.
[0386] In some embodiments, R L1 and R L2 Together with the carbon atom to which they are bonded they form a cyclobutene group.
[0387] In group Ib, in some embodiments, e is 0. In other embodiments, e is 1 and the nitro group can be in any available position of the ring. In some of these embodiments, it is located in the ortho position. In other of these embodiments, it is located in the para position.
[0388] In some embodiments of the fifth aspect of the invention, the enantiomerically enriched form has an enantiomeric ratio greater than 60:40, 70:30, 80:20 or 90: 10. In further embodiments, the enantiomeric ratio is greater than 95:5, 97:3 or 99:1.
[0389] In some embodiments, R L Selected from:
[0390]
[0391]
[0392]
[0393] In some embodiments, R LL is derived from the above R L Group of groups.
[0394] In one embodiment of the first aspect of the present invention, the compound having formula I is:
[0395]
[0396] Further preferences
[0397] In some embodiments, the compound of formula I is P Compounds:
[0398]
[0399] and its salts and solvates, wherein R LP is a linker for attachment to a cell binding agent, the linker being selected from:
[0400] (ia):
[0401]
[0402] in
[0403] Q P yes:
[0404] Where Q XP Make Q P is an amino acid residue, a dipeptide residue or a tripeptide residue;
[0405] X P yes:
[0406]
[0407] Where aP = 0 to 5, bP = 0 to 16, cP = 0 or 1, dP = 0 to 5;
[0408] G L is a linker for attachment to the Ligand unit;
[0409] (ib):
[0410]
[0411] Where R L1 and R L2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropene or cyclobutene group; and
[0412] e is 0 or 1.
[0413] aP can be 0, 1, 2, 3, 4, or 5. In some embodiments, aP is 0 to 3. In some of these embodiments, aP is 0 or 1. In other embodiments, aP is 0.
[0414] bP can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16. In some embodiments, b is 0 to 12. In some of these embodiments, bP is 0 to 8, and can be 0, 2, 4, or 8.
[0415] cP can be 0 or 1.
[0416] dP can be 0, 1, 2, 3, 4, or 5. In some embodiments, dP is 0 to 3. In some of these embodiments, dP is 1 or 2. In other embodiments, dP is 2.
[0417] In X P In some embodiments, aP is 0, cP is 1 and dP is 2, and bP can be from 0 to 8. In some of these embodiments, bP is 0, 4 or 8.
[0418] Where appropriate, the Q of the compounds of formula I described above is X The preference can be applied to Q XP .
[0419] The above G for the compound having formula I L , R L1 , R L2 The preference of and e can be applied to have formula I P of compounds.
[0420] In some embodiments, the conjugate of Formula IV is a P Conjugates of:
[0421] L-(D LP ) p (IV P )
[0422] or a pharmaceutically acceptable salt or solvate thereof, wherein L is a ligand unit (ie, a targeting agent), D LP is a compound having formula III P Drug linker unit:
[0423]
[0424] R LLP is a linker connected to the Ligand unit, the linker being selected from
[0425] (ia'):
[0426]
[0427] Where Q P and X P is as defined above and G LLis a linker attached to the Ligand unit; and
[0428] (ib'):
[0429]
[0430] Where R L1 and R L2 is as defined above; and
[0431] p is an integer from 1 to 20.
[0432] In some embodiments, the compound of formula I is P2 Compounds:
[0433]
[0434] and its salts and solvates, wherein R LP2 is a linker for attachment to a cell binding agent, the linker being selected from:
[0435] (ia):
[0436]
[0437] in
[0438] Q is:
[0439] Where Q X such that Q is an amino acid residue, a dipeptide residue, a tripeptide residue or a tetrapeptide residue;
[0440] X P2 yes:
[0441]
[0442] Where aP2=0 to 5, b1P2=0 to 16, b2P2=0 to 16, cP2=0 or 1, dP2=0 to 5, wherein at least b1P2 or b2P2=0 (i.e., only one of b1 and b2 may not be 0);
[0443] G L is a linker for attachment to the Ligand unit;
[0444] (ib):
[0445]
[0446] Where R L1 and R L2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropene or cyclobutene group; and
[0447] e is 0 or 1.
[0448] aP2 can be 0, 1, 2, 3, 4, or 5. In some embodiments, aP2 is 0 to 3. In some of these embodiments, aP2 is 0 or 1. In other embodiments, aP2 is 0.
[0449] b1P2 can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16. In some embodiments, b1P2 is 0 to 12. In some of these embodiments, b1P2 is 0 to 8, and can be 0, 2, 3, 4, 5, or 8.
[0450] b2P2 can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16. In some embodiments, b2P2 is 0 to 12. In some of these embodiments, b2P2 is 0 to 8, and can be 0, 2, 3, 4, 5, or 8.
[0451] Only one of b1P2 and b2P2 can be non-zero.
[0452] cP2 can be 0 or 1.
[0453] dP2 can be 0, 1, 2, 3, 4, or 5. In some embodiments, dP2 is 0 to 3. In some of these embodiments, dP2 is 1 or 2. In further embodiments, dP2 is 2. In further embodiments, dP2 is 5.
[0454] In X P2 In some embodiments, aP2 is 0, b1P2 is 0, cP2 is 1 and dP2 is 2, and b2P2 can be from 0 to 8. In some of these embodiments, b2P2 is 0, 2, 3, 4, 5 or 8.
[0455] In X P2 In some embodiments, aP2 is 1, b2P2 is 0, cP2 is 0 and dP2 is 0, and b1P2 can be from 0 to 8. In some of these embodiments, b1P2 is 0, 2, 3, 4, 5 or 8.
[0456] In X P2 In some embodiments, aP2 is 0, b1P2 is 0, cP2 is 0 and dP2 is 1, and b2P2 can be from 0 to 8. In some of these embodiments, b2P2 is 0, 2, 3, 4, 5 or 8.
[0457] In X P2In some embodiments, b1P2 is 0, b2P2 is 0, cP2 is 0 and one of aP2 and dP2 is 0. The other of aP2 and dP2 is from 1 to 5. In some of these embodiments, the other of aP2 and dP2 is 1. In other of these embodiments, the other of aP2 and dP2 is 5.
[0458] Where appropriate, the Q of the compounds of formula I described above is X The preference can be applied to formula Ia P2 Q X .
[0459] The above G for the compound having formula I L , R L1 , R L2 The preference of and e can be applied to have formula I P2 of compounds.
[0460] In some embodiments, the conjugate of Formula IV is a P2 Conjugates of:
[0461] L-(D LP2 ) p (IV P2 )
[0462] or a pharmaceutically acceptable salt or solvate thereof, wherein L is a ligand unit (ie, a targeting agent), D LP2 is a compound having formula III P2 Drug linker unit:
[0463]
[0464] R LLP2 is a linker connected to the Ligand unit, the linker being selected from
[0465] (ia'):
[0466]
[0467] Where Q and X P2 is as defined above and G LL is a linker attached to the Ligand unit; and
[0468] (ib'):
[0469]
[0470] Where R L1 and R L2 is as defined above; and
[0471] p is an integer from 1 to 20. BRIEF DESCRIPTION OF THE DRAWINGS
[0472] Figure 1 Mean tumor growth graphs are shown, where ● represents vehicle and ◆ represents ConjA*. DETAILED DESCRIPTION
[0473] Examples
[0474] General information
[0475] use Isolera TM Flash chromatography was performed and the purity of the fractions was checked using thin layer chromatography (TLC). TLC was performed using Merck Kieselgel 60 F254 silica gel with fluorescent indicator on aluminum plates. Visualization of TLC was achieved using UV light.
[0476] Extraction and chromatography solvents were purchased from VWR, UK, and used without further purification.
[0477] Unless otherwise stated, all fine chemicals were purchased from Sigma-Aldrich.
[0478] The PEGylation reagents were obtained from Quanta biodesign, USA, via Stratech, UK.
[0479] LC / MS conditions
[0480] Method A
[0481] Positive mode electrospray mass spectrometry was performed using a Waters Aquity H-class SQD2.
[0482] The mobile phase used was solvent A (water containing 0.1% formic acid) and solvent B (acetonitrile containing 0.1% formic acid). The initial composition of 5% B was kept constant for 25 seconds, and then increased from 5% B to 100% B over a period of 1 minute 35 seconds. The composition was kept at 100% B for 50 seconds, then returned to 5% B within 5 seconds and kept like this for 5 seconds. The total duration of the gradient run was 3.0 minutes. The flow rate was 0.8 mL / minute. Detection was carried out at 254 nm. Column: Waters Acquity BEH ShieldRP18 1.7 μm 2.1 x 50 mm, at 50 °C, equipped with Waters Acquity BEH Shield RP18 VanGuard Precolumn, 130A, 1.7μm, 2.1mm x 5mm.
[0483] Method B
[0484] HPLC (Waters Alliance 2695) was run using a mobile phase of water (A) (formic acid 0.1%) and acetonitrile (B) (formic acid 0.1%).
[0485] The initial composition of 5% B was held constant for 25 seconds, then increased from 5% B to 100% B over a period of 1 minute 35 seconds. The composition was held at 100% B for 50 seconds, then returned to 5% B within 5 seconds and held like this for 5 seconds. The total duration of the gradient run was 3.0 minutes. The flow rate was 0.8 mL / min. Wavelength detection range: 190 to 800 nm. Column: Waters Acquity BEH ShieldRP18 1.7 μm 2.1 x 50 mm, at 50 °C, equipped with Waters Acquity BEHShieldRP18VanGuard Precolumn, 130A, 1.7μm, 2.1mm x 5mm.
[0486] Method C
[0487] HPLC (Waters Alliance 2695) was run using a mobile phase of water (A) (formic acid 0.1%) and acetonitrile (B) (formic acid 0.1%).
[0488] The initial composition 5% B was kept constant for 1 minute, then increased from 5% B to 100% B over a period of 9 minutes. The composition was kept at 100% B for 2 minutes, then returned to 5% B at 0.10 minutes and kept like this for 3 minutes. The total gradient run time was equal to 15 minutes. Flow rate 0.6 mL / min. Wavelength detection range: 190 to 800 nm. Oven temperature: 50°C. Column: ACE Excel2C18-AR, 2μ, 3.0 x 100 mm.
[0489] HPLC conditions
[0490] Reversed-phase ultra-fast liquid chromatography (UFLC) at Shimadzu Prominence TM Using Phenomenex on the machine TM The column was run on a Gemini NX 5μ C18 column (at 50°C) with dimensions of 150 x 21.2 mm. The eluent used was solvent A (H2O containing 0.1% formic acid). 2 O) and solvent B (CH 3CN). All UFLC experiments were performed under the following gradient conditions: initial composition 13% B increased to 30% B over a period of 3 minutes, then increased to 45% B over 8 minutes and to 100% over 6 minutes, then returned to 13% over 2 minutes and maintained for 1 minute. The total duration of the gradient run was 20.0 minutes. The flow rate was 20.0 mL / min and detected at 254 and 223 nm.
[0491] NMR methods
[0492] Proton NMR chemical shift values were measured using a Bruker AV400 at 400 MHz on the delta scale. The following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; quin, quintet; m, multiplet; br, broad. Coupling constants are in Hz.
[0493] Synthesis of key intermediates
[0494]
[0495] a) N-(5,6,7,8-Tetrahydronaphthalen-1-yl)acetamide (I2)
[0496] 5,6,7,8-Tetrahydronaphthalene-1-amine I1 (8.54 g, 58.0 mmol) was dissolved in dichloromethane (80 mL). Triethylamine (18 mL, 129 mmol) was added and the mixture was cooled to 0 °C. Acetic anhydride (11.5 mL, 122 mmol) was added dropwise, and after the addition was complete, the reaction mixture was warmed to rt and stirred for 45 min, after which LCMS indicated the reaction was complete. The mixture was washed with CH 2 Cl 2 Dilute with HO 2 O, saturated NaHCO 3 , 10% citric acid, and the organic phase was washed with MgSO 4 Dry and concentrate in vacuo. The off-white solid was mixed with 1:3 Et 2 O / isohexane trituration to give I2 (10.8 g, 57.1 mmol, 98% yield) as a white solid, used without further purification. LC / MS (Method A): Retention time 1.44 min (ES+) m / z 190 [M+H] +
[0497] b) N-(4-nitro-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (I3)
[0498] N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide I2 (1.00 g, 5.2840 mmol) was added portionwise to sulfuric acid (15 mL, 281 mmol) at -5 °C. Sodium nitrate (450 mg, 5.2945 mmol) was added portionwise to the reaction mixture and stirred at -5 °C for 30 min, after which LCMS indicated no further reaction progress. The reaction mixture was poured into ice under external cooling, and the aqueous mixture was washed with CH 2 Cl 2 The organic phase was extracted with MgSO 4 Dry and purify by Isolera (10%-80% EtOAc in isohexane) to give a mixture of N-(4-nitro-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide I3 and N-(2-nitro-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide as a white / yellow solid (956 mg, 4.0811 mmol, 77% yield). LC / MS (Method A): Retention time 1.53 min (ES+) m / z 235 [M+H] + .
[0499] c) N-(4-nitro-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (I4)
[0500] N-(4-nitro-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide I3 (1.01 g, 4.31 mmol) was dissolved in acetone (30 mL). Magnesium sulfate (3.9 mL, 5.9 mmol, 1.5 mol / L) was added to water and the mixture was cooled to 0 °C. Potassium permanganate (2.07 g, 13.0 mmol) was added to the reaction mixture in batches and the mixture was warmed to rt and stirred for 50 min, after which TLC indicated that the reaction was complete. The reaction mixture was filtered through diatomaceous earth, the solid was washed with CHCl3 and the resulting organic mixture was washed with H 2 O, washed with brine, and MgSO 4 Dry and purify by isolera (20%-50% EtOAc in isohexane) to give a mixture of N-(4-nitro-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide I4 and N-(2-nitro-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide as a white / yellow solid (709 mg, 2.86 mmol, 66%). LC / MS (Method A): Retention time 1.44 min (ES+) m / z 190 [M+H] +
[0501] d) 8-Amino-5-nitro-3,4-dihydronaphthalen-1(2H)-one (I5)
[0502] A mixture of N-(4-nitro-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide I4 and N-(2-nitro-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (709 mg, 2.8561 mmol) and 6N hydrochloric acid (7 mL) were stirred at 80 ° C for 2.5 h, after which LCMS indicated that the reaction was complete. The reaction mixture was cooled in an ice bath, and 6N NaOH solution was added until the pH was basic. The aqueous mixture was washed with CH 2 Cl 2 The organic phase was extracted with MgSO 4 Dried and concentrated in vacuo. Isolera (0%-50% EtOAc in isohexane) afforded 8-amino-5-nitro-3,4-dihydronaphthalen-1(2H)-one I5 (320 mg, 1.552 mmol, 54% yield) as a yellow / orange solid. LC / MS (Method A): Retention time 1.54 min (ES+) m / z 207 [M+H] +
[0503] e) 2,2,2-Trifluoro-N-(4-nitro-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (I6)
[0504] 8-Amino-5-nitro-3,4-dihydronaphthalen-1(2H)-one I5 (430 mg, 2.0854 mmol) was dissolved in dichloromethane (20 mL). Pyridine (340 μL, 4.20 mmol) was added and the mixture was cooled to 0°C. Trifluoroacetic anhydride (590 μL, 4.197 mmol) was added and stirred for 30 min, after which LCMS indicated the reaction was complete. The mixture was washed with CH 2 Cl 2 Dilute with HO 2 O, and the organic phase was washed with MgSO 4 Drying and concentration in vacuo gave 2,2,2-trifluoro-N-(4-nitro-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide I6 (630 mg, 2.0846 mmol, >99% yield) as a yellow solid which was used without further purification. LC / MS (Method A): Retention time 1.86 min (ES+) m / z 301X [MH] -
[0505] f) N-(4-amino-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)-2,2,2-trifluoroacetamide (I7)
[0506] Zinc (2.73 g, 41.7 mmol) was suspended in methanol (80 mL), formic acid (4 mL) and water (4 mL), and the mixture was cooled to 0°C. 2,2,2-Trifluoro-N-(4-nitro-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide I6 (568 mg, 2.0865 mmol) was added in portions and the mixture was stirred at 0°C for 30 minutes, after which LCMS indicated the reaction was complete. The reaction mixture was filtered, the filtrate was diluted with EtOAc and saturated NaHCO 3 Wash the organic phase with MgSO 4 Drying and concentration in vacuo gave N-(4-amino-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)-2,2,2-trifluoroacetamide I7 (568 mg, 2.0865 mmol, >99% yield) as a yellow solid, which was used without further purification. LC / MS (Method A): Retention time 1.65 min (ES+) m / z 273 [M+H] +
[0507] g) N-(4-acetamido-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)-2,2,2-trifluoroacetamide (I8)
[0508] N-(8-amino-4-oxo-tetrahydronaphthalen-5-yl)-2,2,2-trifluoro-acetamide I7 (568 mg, 2.0865 mmol) was dissolved in dichloromethane (20 mL). Triethylamine (580 μL, 4.16 mmol) was added followed by acetyl chloride (297 μL, 4.173 mmol) and the mixture was stirred for 30 min, after which LCMS indicated the reaction was complete. The reaction mixture was washed with CH 2 Cl 2 Dilute with HO 2 O, and the organic phase was washed with MgSO 4 Drying and concentration in vacuo gave N-(8-acetamido-4-oxo-tetrahydronaphthalen-5-yl)-2,2,2-trifluoro-acetamide I8 (655 mg, 2.084 mmol, >99% yield) as a yellow solid which was used without further purification. LC / MS (Method A): Retention time 1.55 min (ES+) m / z 315 [M+H] +
[0509] h) N-(4-amino-5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (I9)
[0510] N-(8-Acetamido-4-oxo-tetrahydronaphthalen-5-yl)-2,2,2-trifluoro-acetamide I8 (2.77 g, 8.81 mmol) was dissolved in methanol (240 mL) and water (17 mL). Potassium carbonate (4.88 g, 35.3 mmol) was added and the mixture was stirred at 50 °C for 1.5 h, after which LCMS indicated the reaction was complete. The reaction mixture was cooled, concentrated in vacuo, and dissolved in CH 2 Cl 2 in 10% MeOH and washed with HO 2 O. The organic phase was washed with MgSO 4 The mixture was dried and purified by isolera chromatography (2%-15% MeOH in CH 2 Cl 2 The 1-hydroxy-1-nitro-2-nitro-4-nitro-2-ol (2-nitro-2-nitro-4-ol) was purified from the solution in 4% paraffin (5% paraffin) to give N-(8-amino-1-oxo-tetrahydronaphthalen-5-yl)acetamide I9 (1.20 g, 5.50 mmol, 62.3% yield) as a yellow solid. LC / MS (Method A): retention time 0.98 min (ES+) m / z 219 [M+H] +
[0511]
[0512] i) (S)-N-(9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)acetamide (I10)
[0513] N-(8-amino-1-oxo-tetralin-5-yl)acetamide I9 (641 mg, 2.94 mmol, 1.0 eq), (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione A3 (840 mg, 3.19 mmol, 1.1 eq) and PPTS (740 mg, 2.95 mmol, 1.0 eq) were dissolved in toluene (60 mL) and stirred at reflux for 3 h, after which LCMS indicated that I9 had been consumed. The reaction mixture was cooled and concentrated in vacuo. The resulting solid was triturated with acetonitrile and then acetone to give I10 as a brown solid with slight TsOH contamination (1.26 g, 96%). LC / MS (Method A): Retention time 1.32 min (ES+) m / z 447 [M+H] +
[0514] j) (S)-4-amino-9-ethyl-9-hydroxy-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione (I11)
[0515] (S)-N-(9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)acetamide (I10) (1.26 g, 2.83 mmol, 1.0 equiv) was dissolved in H 2 The mixture was stirred at 80 °C for 5 h, after which LCMS indicated that I10 had been consumed. The reaction mixture was washed with H 2 O and concentrated in vacuo to give (S)-4-amino-9-ethyl-9-hydroxy-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione I11 (1.51 g, 2.85 mmol, 90% mass, 101% yield) as a red crystalline solid. LC / MS (Method A): retention time 1.36 min (ES+) m / z 405 [M+H] + .
[0516] Alternative synthesis of I11
[0517]
[0518] IPC, purity and assay of this synthesis
[0519]
[0520]
[0521] a) 5-Bromo-8-nitro-tetralin-1-one (I13)
[0522] Under nitrogen, a solution of potassium nitrate (1.15 eq., 13.83 g) dissolved in sulfuric acid (concentrated, 5.0 rel. vol., 160 mL) was added (addition time 4-12 h, keeping the temperature below 10° C.) to a solution of 5-bromotetralin-1-one (I12) (1.0 eq., 26.77 g) in sulfuric acid (concentrated, 5.0 rel. vol., 160 mL). When the reaction was complete, the reaction mixture was transferred to a flask containing water (36 rel. vol., 1.15 L), adjusting the transfer rate to keep the temperature below 10° C. The resulting solid was filtered, washed three times with water (4.0 rel. vol., 128 mL) and then dried at about 40° C. for 24 h. The dried filter cake was dissolved in a mixture of acetone (2.5 rel. vol., 80 mL) and water (0.38 rel. vol., 12.2 mL) (heated to about 75° C.) and then cooled to about 20° C. The resulting solid was removed by filtration. The solvent was exchanged to ethanol by distillation and the solution volume was reduced to 2.0 rel vols (64 mL). The solution was cooled to about 25°C and the resulting solid was collected by filtration. The solid was washed with ethanol (1.0 rel vols, 32 mL) and then dried under vacuum at 40°C to give 5-bromo-8-nitro-tetralin-1-one I13 (15.36 g, 40%) as a brown solid; RT 14.0 min
[0523] Method 1 IPC, purity and determination of bromo-8-nitro-tetralin-1-one.
[0524]
[0525]
[0526] b) N-(8-Nitro-1-oxo-tetrahydronaphthalen-5-yl)acetamide (I14)
[0527] A solution of bromo-8-nitro-tetralin-1-one (I13) (1.0 eq., 18.0 g, 90.6% ww), acetamide (1.2 eq., 4.72 g), tris(dibenzylideneacetone)dipalladium(0) (0.01 eq., 0.61 g) potassium phosphate (1.4 eq., 19.8 g) in dioxane (15 rel. vol., 270 mL) was heated to about 70°C under nitrogen. When the reaction was complete, the solution was cooled to about 20°C and diluted with dioxane (5 rel. vol., 90.0 mL) and filtered. The solvent was exchanged with ethanol and the volume was reduced to a total reaction volume of 3 rel. vol. (54.0 mL). The solution was cooled to about 20°C and the resulting solid was collected by filtration and washed with MTBE (methyl tert-butyl ether) (1.0 rel. vol., 18.0 mL). The solid was dried under vacuum at 40 °C to give N-(8-nitro-1-oxo-tetralin-5-yl)acetamide I14 (10.0 g, 60.6%) as a dark yellow solid; RT 8.86 min.
[0528] c) N-(8-amino-1-oxo-tetrahydronaphthalen-5-yl)acetamide (I15)
[0529] Palladium hydroxide on carbon (20% w / w, 0.15 eq., 5.25 g) was added to a solution of N-(8-nitro-1-oxo-tetrahydronaphthalene-5-yl)acetamide (I14) (1.0 eq., 32.6 g) in methanol (40 rel. vols, 1250 mL). The reaction mixture was placed under a hydrogen atmosphere (about 40 psi) at about 40 °C for 8 h. The hydrogen was removed and replaced with nitrogen, and the catalyst was removed by filtering through cellulose, and the cellulose was washed with methanol (4.0 rel. vols, 130 mL). The solution volume was reduced to 4.0 rel. vols by distillation and then diluted with MTBE (4 rel. vols, 130 mL). The resulting solid was collected by filtration, washed with MTBE (2 rel vols, 65 mL) and dried under vacuum at 40 °C to give N-(8-amino-1-oxo-tetralin-5-yl)acetamide I15 as a gray-green solid (21.1 g, 77.8%; RT 5.44 min.d) 5,8-Diaminotetralin-1-one (I16)
[0530] A solution of N-(8-amino-1-oxo-tetrahydronaphthalene-5-yl)acetamide (I15) (1.0 equivalents, 10.0 g) in hydrochloric acid (5 M, 6.0 relative volumes, 60 mL) was maintained at approximately 90 ° C for 3 h. The temperature was reduced to 25 ° C and sodium hydroxide (2 M, 4.0 relative volumes, 40 mL) was added until pH 10.0 was reached, keeping the temperature at 25 ° C. The resulting solid was collected by filtration and washed with water (2.0 relative volumes, 20 mL). The wet cake was dissolved in tetrahydrofuran (60 relative volumes, 600 mL) and filtered. The solution was concentrated to 5.0 relative volumes and heptane (20 relative volumes, 200 mL) was added. The solution was concentrated to 10.0 relative volumes and heptane (20 relative volumes, 200 mL) was further added, and then the volume was reduced to 10.0 relative volumes again. The resulting solid was collected by filtration and washed with heptane (5.0 relative volumes, 50 mL). The solid was dried under vacuum at 40 °C for 17 h to give 5,8-diaminotetralin-1-one (I16) (6.90 g, 82.7%) as a yellow solid; 1H NMR (400 MHz DMSO-d6) δ ppm 1.82 (m, 2H), 2.38 (t, J = 2.0 Hz, 2H), 2.47 (t, J = 2.0 Hz, 2H), 6.34 (d, J = 2.0 Hz, 1H), 6.68 (d, J = 2.0 Hz, 1H); RT 3.90 e) (S)-4-amino-9-ethyl-9-hydroxy-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione (I11)
[0531] By 5,8-diaminotetralin-1-one (I16) (1.0 equivalent, 5.0g), (4S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrans also [3,4-f] indolizine-3,6,10-trione (A3) (1.06 equivalent, 7.9g) and p-toluenesulfonic acid pyridinium (1.0 equivalent, 7.2g) solution in toluene (50.0 relative volumes, 250mL) is maintained at 120 DEG C and continues 15h.The volume of solution is reduced to 2.0 relative volumes, and then diluted with acetonitrile (20 relative volumes, 100mL) and water (20 relative volumes, 100mL).Gained slurry is filtered and solid is washed with acetonitrile aqueous solution (1:1,20 relative volumes, 100mL). The solid was slurried with aqueous methanol (water:MeOH 3:1, 40 rel vols, 200 mL), filtered and washed with aqueous methanol (1:1, 20 rel vols, 100 mL). The solid was slurried with water (60 rel vols, 300 mL) at 50 °C, filtered and washed with water (10 rel vols, 50 mL). The solid was slurried with aqueous acetonitrile (water:acetonitrile, 1:3, 40 rel vols, 200 mL) at 30 °C, filtered and washed with aqueous acetonitrile (water:acetonitrile, 1:3, 5 rel vols, 50 mL) and then dried under vacuum at 40 °C to give (S)-4-amino-9-ethyl-9-hydroxy-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione (I11) (5.0 g, 43.7%) as a white solid; RT 5.13.
[0532] Synthesis of I18
[0533]
[0534] a) tert-Butyl (S)-(2-((2-((1-((2-((4-amino-5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)amino)-2-oxoethyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)amino)-2-oxoethyl)carbamate (I17)
[0535] Boc-GGFG-OH (227 mg, 0.52 mmol) and EEDQ (157 mg, 0.634 mmol) were dissolved in CH 2 Cl 2(25 mL) and the mixture was stirred for 15 min until the peptide dissolved into the solution. Compound I16 (100 mg, 0.56747 mmol) was then added and the mixture was stirred until completion. After 1 h, LVMC showed that the reaction was 90% complete. The mixture became thicker as the product crashed out. The mixture was left for another hour and then vacuumed to dryness. The crude product was taken up in Et 2 O (50 mL). The solid was filtered and then taken up in CH 2 Cl 2 (50 mL) for further purification. The solid was filtered and dried to give the product I17 (273 mg, 0.459 mmol, 80.9% yield) as a grey solid. Analytical data: LCMS 3 min: ES + =1.46min, m / z 595.7[M+H] .+ .
[0536] b) (S)-2-(2-(2-aminoacetamido)acetamido)-N-(2-(((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)amino)-2-oxoethyl)-3-phenylpropanamide (I18)
[0537] Aniline I17 (450 mg, 1.045 mMol), lactone A5 (280 mg, 1.064 mMol) and pyridinium p-toluenesulfonate (273 mg, 1.086 mMol) were dissolved in toluene (20 mL) and the mixture was heated to 150 °C (high reflux). MeOH (4 mL) was added to help dissolve the mixture. After 7 h, the crude reaction was vacated down to dryness. The crude product was purified by silica gel chromatography (CHCl 3 / MeOH, 100% to 65:35) to give the product I18 (259 mg, 0.359 mMol, 78.1 yield). Analytical data: LCMS 3min: ES + =1.17min, m / z 722.8[M+H] .+ .
[0538] Alternative synthesis of I16
[0539]
[0540] a) 5-Fluoro-8-nitro-tetralin-1-one (I20)
[0541] In a 3-necked round-bottom flask, 5-fluorotetralin-1-one I19 (4.7 g, 29 mmol) was dissolved in 1 / 2 amount of sulfuric acid (120 mL). The mixture was stirred until all solids dissolved and then cooled to 0°C-5°C. In a dropping funnel, potassium nitrate (3 g, 29.6730 mmol) was dissolved in the remaining half of sulfuric acid (120 mL) at 0°C-5°C. Slowly added to the SM mixture, ensuring that the solution was kept cold (45 min). Stirred until complete at 0°C-5°C. The reaction mixture was subsequently quenched with water (250 mL), and stirred at 0°C-5°C. The solid was filtered and washed with water (50 mL). The solid was dried in a vacuum oven at 50°C for 2 h. The crude solid was heated to 40°C in Et 2 O overnight, then cooled to 0 °C and filtered. The wet cake was washed with more cold Et 2 O (50 mL) and dried in a vacuum oven at 50 °C to give the pure product I20 (5.5 g, 26 mmol, 92% yield) as a light pink fine powder. LCMS (Method B): ES + =1.55min, m / z 210.1[M+H] .+ .
[0542] b) 5-amino-8-nitro-tetralin-1-one (I21)
[0543] Compound I20 (2.7 g, 13 mmol) was dissolved in CH 3 CN (2.5 mL) and in H 2 NH in O (8 mL, 40 mmol) 4 OH (21% by mass) was added to a sealed pressure tube and heated to 185° C. Once completed, the mixture was transferred to a round bottom flask and evacuated. The crude product was purified by silica gel column chromatography (CHCl 3 / MeOH; 100 to 99:1) to give the pure product I21 (1.1 g, 5.3 mmol, 41% yield) as a black solid. LCMS (Method B): ES + =1.34min, m / z 207.1[M+H] .+ .
[0544] c) 5,8-Diaminotetralin-1-one (I16)
[0545] Compound I21 (1.35 g, 6.55 mmol) was dissolved in methanol (20 mL), H 2 To a mixture of 10% formic acid (1 mL) and 2% formic acid (1 mL) was added zinc (8.5 g, 130 mmol) slowly, making sure to keep the temperature below 40 °C. More formic acid / H 2O (0.5 mL) was added to drive the reaction to completion. The reaction mixture was filtered, and the filtrate was washed with EtOAc and CH 2 Cl 2 The crude product was dried and loaded onto a silica gel column (CHCl 3 / EtOAc; 100 to 7:3 then CHCl 3 / MeOH; 99:1 to 98:2) to give the pure product I16 (1.015 g, 5.760 mmol, 88.0% yield). LCMS (Method B): ES + = 0.2 min, m / z not observed.
[0546] Example 1
[0547]
[0548] a) Allyl ((S)-3-methyl-1-oxo-1-(((S)-1-oxo-1-((5-oxo-4-(2,2,2-trifluoroacetamido)-5,6,7,8-tetrahydronaphthalen-1-yl)amino)propan-2-yl)amino)butan-2-yl)carbamate (A1)
[0549] DCC (6.54 g, 31.7 mMol) and HOPO (3.36 g, 30.2 mMol) were added to a mixture of allyloxycarbonyl-Val-Ala-OH (9.09 g, 31.7 mmol) and I7 (7.85 g, 28.8 mMol) in CH 2 Cl 2 The resulting mixture was stirred overnight. The white solid formed during the reaction was filtered off and washed with cold CH 2 Cl 2 The filtrate was washed with water (150 mL) and brine (150 mL). The organic layer was purified by MgSO 4 Dry, filter and evaporate. The crude product was purified by silica gel chromatography (Hex / EtOAc, 60:40). The isolated product A1 was contaminated by co-eluting DCU (21.1 g, 140% yield). LC / MS (Method B): ES + =1.81min, m / z 527.6[M+H] .+ .
[0550] b) Allyl ((S)-1-(((S)-1-((4-amino-5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (A2)
[0551] The protected aniline A1 (18 g, 34.19 mMol) was dissolved in MeOH and H 2 O 10:1 (165 mL) and K 2 CO 3 (10 g, 72.36 mMol). The mixture was stirred at 50 °C until completion. The mixture was evacuated to almost dryness and the residue was washed with CH 2 Cl 2 Absorb and use H 2 O and brine, then MgSO 4 Dry, filter and evaporate. The crude product was chromatographed on silica gel (CHCl 3 / MeOH, 100% to 7:3). The isolated product A2 was contaminated with co-eluting impurities (10.71 g, 73% yield). LC / MS (Method B): ES + =1.46min, m / z 431.7[M+H] .+ .
[0552] c) Allyl ((S)-1-(((S)-1-(((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)amino)-1-oxopropyl-2-yl)amino)-3-methylbutyl-2-yl)carbamate (A4)
[0553] Aniline A2 (450 mg, 1.045 mMol), lactone A3 (280 mg, 1.064 mMol) and pyridinium p-toluenesulfonate (273 mg, 1.086 mMol) were dissolved in toluene (20 mL) and the mixture was heated to 130 °C (high reflux). A few drops of MeOH were added from time to time to help dissolve the mixture. After 7 h, the crude reaction was vacated down to dryness. The crude product was purified by silica gel chromatography (CHCl 3 / MeOH, 100% to 95:5) to give the product A4 (360 mg, 52.3% yield). LC / MS (Method B): ES + =1.51min, m / z 658.8[M+H] .+ .
[0554] d) Allyl (S)-2-amino-N-((S)-1-(((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)amino)-1-oxopropan-2-yl)-3-methylbutanamide (A5)
[0555] Excess piperidine (642 μL) was added to A4 (543 mg, 0.82 mMol) and PdP (Ph 3 ) 4 (89 mg, 0.08 mMol) in CH 2 Cl 2 The mixture was allowed to stir at room temperature for 20 min, at which time the reaction was complete (as monitored by LC / MS). The reaction mixture was washed with CH 2 Cl 2 (25 mL) and the organic phase was diluted with H 2 O (25 mL) and brine (25 mL). The organic phase was washed with MgSO 4 Dry, filter, and remove excess solvent by rotary evaporation under reduced pressure to give the crude product A5, which was used as such in the next step. LC / MS (Method B): ES + =1.15min, m / z 574.6[M+H] .+ .
[0556] e) 1-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propionamido)-N-((S)-1-(((S)-1-(((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-3,6,9,12,15,18,21,24-octaoxaheptacosane-27-amide (1)
[0557] Under argon atmosphere, pyridine (83 μL, 1.03 mMol) and Mal-dPEG were added. 8 -OTFP (767 mg, 1.03 mMol) was added to crude A5 (assumed to be 1.03 mMol) in dry CH 2 Cl 2 The reaction was stirred overnight, and due to incomplete reaction, 0.5 equivalent of Mal-dPEG was added. 8-OTFP in an attempt to promote the reaction. 2 Cl 2 (25 mL) and the organic phase was diluted with H 2 O (2 x 50 mL) and brine, then MgSO 4 The crude product was purified by reverse phase HPLC (HPLC) and the excess solvent was removed by rotary evaporation under reduced pressure. 2 O / CH 3 CN + 0.05% FA gradient) and freeze-dried to give 1 (1.189 g, 31% yield over 2 steps). LC / MS (Method B): ES + =1.43min, m / z 1149.3[M+H] .+ . LC / MS (Method C): ES + =5.37min, m / z 1149.4[M+H] .+ .
[0558] Example 2
[0559]
[0560] 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-(((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)hexanamide (2)
[0561] Under argon atmosphere, Mal-hexanoic acid (56 mg, 0.26 mMol) and EDCI.HCl (51 mg, 0.26 mMol) were added to the crude A5 (assumed to be 0.26 mMol) in dry CH 2 Cl 2 The reaction was stirred overnight, and due to incomplete reaction, another 0.5 equivalent of Mal-hexanoic acid and EDCI.HCl were added. 2 Cl 2 (25 mL) and the organic phase was diluted with H 2 O (2 x 50 mL) and brine, then MgSO 4 Dry, filter and remove excess solvent by rotary evaporation under reduced pressure. The crude product was purified by silica gel column chromatography (CHCl 3 / MeOH 95:5) to give 2 (31.6 mg, 20% yield over 2 steps). LC / MS (Method B): ES + =1.56min, m / z 767.8[M+H] .+ . LC / MS (Method C) 15min: ES + =6.05min, m / z 767.8[M+H] .+ .
[0562] Example 3
[0563]
[0564] (S)-2-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)acetamido)-N-((S)-1-(((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)amino)-1-oxopropan-2-yl)-3-methylbutanamide (3)
[0565] Under argon atmosphere, azide-dPEG 3 -acid (77.5 mg, 0.31 mMol) and EDCI.HCl (60 mg, 0.31 mMol) were added to the crude A5 (assumed to be 0.31 mMol) in anhydrous CH 2 Cl 2 The reaction was stirred overnight, and due to incomplete reaction, another 0.5 equivalents of azide-dPEG was added. 3 -OH and EDCI.HCl. The reactants were treated with CH 2 Cl 2 (25 mL) and the organic phase was diluted with H 2 O (2 x 50 mL) and brine, then MgSO 4 Dry, filter and remove excess solvent by rotary evaporation under reduced pressure. The crude product was purified by preparative HPLC and the fractions were freeze-dried to give pure 3 (92.2 mg, 24.7% yield over 2 steps). LC / MS (Method B): ES + =1.69min, m / z 789.9[M+H] .+ . LC / MS (Method C): ES + =6.68min, m / z 790.0[M+H] .+ .
[0566] Example 4
[0567]
[0568] N-((S)-1-(((S)-1-(((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-4,7,10,13,16-pentaoxanonadecan-18-ynamide (4)
[0569] Under argon atmosphere, propargyl-dPEG 5 -acid (56 mg, 0.19 mMol) and EDCI.HCl (37 mg, 0.19 mMol) were added to the crude A5 (assumed to be 0.19 mMol) in anhydrous CH 2 Cl 2 The reaction was stirred overnight, and due to incomplete reaction, another 0.5 equivalent of propargyl-dPEG was added 5 -OH and EDCI.HCl. The reactants were treated with CH 2 Cl 2 (25 mL) and the organic phase was diluted with H 2 O (2 x 50 mL) and brine, then MgSO 4 Dry, filter and remove excess solvent by rotary evaporation under reduced pressure. The crude product was purified by preparative HPLC and the fractions were freeze-dried to give pure 4 (22 mg, 16.7% yield over 2 steps). LC / MS (Method B): ES + =1.54min, m / z 860.9[M+H] .+ . LCMS (Method C): ES + =5.57min, m / z 860.9[M+H] .+ .
[0570] Example 5
[0571]
[0572] (S)-2-(2-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)phenyl)acetamido)-N-((S)-1-(((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)amino)-1-oxopropan-2-yl)-3-methylbutanamide (5)
[0573] PM-acetate-OSu (64 mg, 0.19 mMol) was added to crude A5 (assumed to be 0.19 mMol) in anhydrous CH 2 Cl 2 (10 mL). The reaction did not proceed, so DIPEA (51 μL, 0.28 mMol) was added. The reaction was stirred until completion. The mixture was washed with CH 2 Cl 2 (25 mL) and the organic phase was diluted with H 2 O (2 x 50 mL) and brine, then MgSO 4 Dry, filter and remove excess solvent by rotary evaporation under reduced pressure. The crude product was purified by preparative HPLC and the fractions were freeze-dried to give pure 5 (2.5 mg, 1.6% yield over 2 steps). LC / MS (Method B): ES + =1.54min, m / z 787.7[M+H] .+ . LC / MS (Method C): ES + =5.61min, m / z 787.8[M+H] .+ .
[0574] Example 6
[0575]
[0576] (R)-2-((3-nitropyridin-2-yl)disulfanyl)propyl((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)carbamate (6)
[0577] (i) (2R)-2-[(3-nitro-2-pyridyl)disulfanyl]propan-1-ol A6 (25 mg, 0.1015 mmol, 1.0 eq) was dissolved in dichloromethane (1 mL). Pyridine (8.5 μL, 0.11 mmol, 1.0 eq) was added followed by triphosgene (11 mg, 0.0370685 mmol, 0.33 eq) and the mixture was stirred under Ar for 45 min followed by LCMS (Et 2 NH quenching) indicated the formation of the corresponding carbamate.
[0578] (ii) (S)-4-amino-9-ethyl-9-hydroxy-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizine[1,2-b]quinoline-10,13-dione (I11) (43mg, 0.09026mmol, 1.0 equivalent) was dissolved in dichloromethane (2mL), N,N-diisopropylethylamine (42μL, 0.241mmol, 2.7 equivalents) and pyridine (25μL, 0.309mmol, 3.4 equivalents). The reaction mixture from step (i) was added and the mixture was stirred for 30min, and then LCMS showed that the reaction was complete. The reaction mixture was concentrated in vacuo and purified by isolera chromatography (0%-4% MeOH in CH 2 Cl 2 6 (22 mg, 0.03256 mmol, 36% yield, QC = 96.8%) as a yellow solid. LC / MS (Method B): RT = 1.86 min, 676.6 [M+H] + .
[0579] Example 7
[0580]
[0581] 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(2-((2-(((S)-1-((2-(((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)amino)-2-oxoethyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)amino)-2-oxoethyl)hexanamide (7)
[0582] Compound I18 (259 mg, 0.3588 mmol) was dissolved in CH 2 Cl 2(25mL). The starting material was completely insoluble, so DMA (1mL) was added. Since no improvement was observed, DIPEA (68μL, 0.390mmol) was added, and all solids went into solution. Maleimidocaproic acid (69mg, 0.358mmol) was added and the mixture was stirred at rt overnight, when LCMS analysis showed that the reaction was complete. The reaction mixture was quenched with MeOH (2mL) and evacuated to dryness. The crude product was purified by preparative HPLC and then freeze-dried to give compound 7 (38.2mg, 11% yield) as an ochre solid. Analytical data: LCMS 3min: ES + =1.47min, m / z 916.2[M+H] .+ LCMS15min:ES + =5.46min, m / z 916.1[M+H] .+ .
[0583] Example 8
[0584]
[0585] 1-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propionamido)-N-(2-((2-(((S)-1-((2-(((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)amino)-2-oxoethyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)amino)-2-oxoethyl)-3,6,9,12,15,18,21,24-octaoxaheptacosane-27-amide (8)
[0586] Compound I18 (70 mg, 0.096 mmol) was dissolved in CH 2 Cl 2 (5 mL). The starting material did not dissolve at all, so DMA (0.5 mL) was added. No improvement was observed, so DIPEA (19 μL, 0.106 mmol) was added and all the solid went into solution. Mal-dPEG was added 8-OH (63 mg, 0.106 mmol) and EDCI.HCl (19 mg, 0.099 mMol) and the mixture was stirred at rt overnight, when LCMS analysis showed that the reaction was complete. The reaction mixture was quenched with MeOH (2 mL) and evacuated to dryness. The crude product was purified by preparative HPLC and then freeze-dried to give 8 (30 mg, 24% yield) as an ochre solid. LCMS 3 min: ES + =1.44min, m / z 1297.6[M+H] .+ .
[0587] Alternative Synthesis of Example 9-1
[0588]
[0589] (S)-4-Amino-9-ethyl-9-hydroxy-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione I11 (371 mg, 0.779 mmol, 1.0 equiv) was dissolved in dichloromethane (30 mL). N,N-diisopropylethylamine (69 μL, 0.396 mmol, 0.51 eq.), and (2S)-2-[[(2S)-2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-3-methyl-butanoyl]amino]propanoic acid (664 mg, 0.871 mmol, 1.1 eq.) in N,N-dimethylacetamide (10 mL) were added followed by EDCI.HCl (226 mg, 1.18 mmol, 1.5 eq.) and the mixture was stirred for 2 h before LCMS indicated good conversion but the reaction had stalled. The reaction mixture was warmed to 30 °C and stirred for 30 min, LCMS indicated no change so CH 2 Cl 2 And Et 2 O was added to the resulting DMA solution. The precipitated oil was collected and Et 2 O and repeat the precipitation process. The combined precipitates were purified by HPLC (10%-60% B in A for 13 min) to give 1 (200 mg, 0.174 mmol, 98% purity, 22% yield) as a yellow residue after freeze drying. LC / MS (Method A): Retention time 1.44 min (ES+) m / z 1149 [M+H] +
[0590] 1 H NMR (600MHz, chloroform-d) δ8.81(s,1H),7.83(s,2H),7.48(s,1H),7.18(dd,J=18.7,7 .5Hz,2H),6.69(s,2H),6.43(s,1H),5.68(d,J=16.1Hz,1H),5.27(d,J=16.1Hz ,1H),5.03(d,J=18.4Hz,1H),4.90(d,J=18.4Hz,1H),4.75(p,J=7.2Hz,1H),4. 32(dd,J=7.4,5.8Hz,1H),4.05(s,1H),3.83(t,J=7.2Hz,3H),3.78-3.68(m,3H ),3.68-3.57(m,31H),3.53(t,J=5.1Hz,3H),3.40(q,J=5.3Hz,2H),3.06-2.91 (m,3H),2.84(dt,J=16.3,6.2Hz,1H),2.63(ddd,J=14.8,8.5,4.2Hz,1H),2.57 -2.44(m,4H),2.30(dq,J=13.4,6.7Hz,1H),2.10(p,J=6.4Hz,3H),1.91(ddt,J =16.8, 14.3, 7.2Hz, 3H), 1.54 (d, J = 7.1Hz, 3H), 1.02 (dd, J = 15.5, 6.9Hz, 10H).
[0591] Example 10-Alternative Synthesis of A2
[0592]
[0593] Allyl ((S)-1-(((S)-1-((4-amino-5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (A2)
[0594] EDCI.HCl (7.71 g, 31.2 mmol) was added to allyloxycarbonyl-Val-Ala-OH (8.49 g, 31.2 mmol) in CH 2 Cl 2 (200 mL) and stirred for 15 min or until dissolved. I16 (5 g, 28.3 mMol) was then added and the resulting mixture was stirred until the reaction was complete. The volatiles were removed under reduced pressure. The crude product was taken up in Et 2O (50 mL) and the mixture was sonicated for 3 min. The solid was filtered and taken up again in CH2Cl2 (50 mL), sonicated for 3 min and filtered again to give the pure product A2 (12.21 g, 79% yield) as a grey solid. LC / MS (Method B): ES + =1.47min, m / z 431.5[M+H] .+ .
[0595] Example 11
[0596]
[0597] a)(9H-fluoren-9-yl)methyl N2-(1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxo-4-azatrionecan-31-yl)-N5-((S)-1-(((S)-1-(((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-L-glutamine (A7)
[0598] EDCI.HCl (0.10 mmol, 1.2 eq.) was added to A5 (0.087 mmol, 1.0 eq.) and Mal-PEG 8 -Glu-OH (0.10 mmol, 1.2 eq) in DCM (5 mL) was added and the resulting mixture was stirred at room temperature overnight. The reaction mixture was evaporated to dryness and purified by column (8%-12% MeOH / DCM) to give the product as a white solid. Yield = 80 mg (63%). LC / MS (Method B) rt 1.66 min m / z (1456.2) M+H.
[0599] b) N2-(1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxo-4-azahexanedionecan-31-yl)-N5-((S)-1-(((S)-1-(((S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-L-glutamine (9)
[0600] 1-Methylpyrrolidine (200 μL) was added to a solution of A7 (0.06 mmol) in DMF (0.8 mL) and stirred at room temperature for 10 min. The solvent was removed under vacuum and the residue was purified by preparative HPLC (30% MeCN / water + 0.05% formic acid over 8.5 min). The fractions containing the product were freeze-dried to give the product as a white solid. Yield = 23 mg (30%). LC / MS (Method B) rt 1.43 min m / z (1278.4) M+H.
[0601] Example 12 - Conjugation
[0602] Herceptin-C239i Antibody
[0603] The Herceptin antibody was engineered to have a cysteine inserted between positions 239 and 240 following the method described in Dimasi, N., et al., Molecular Pharmaceutics, 2017, 14, 1501-1516 (DOI: 510.1021 / acs.molpharmaceut.6b00995).
[0604] Conj
[0605] A solution of 50 mM DL-dithiothreitol (DTT) in phosphate buffered saline (pH 7.4) (PBS) (150 molar equivalents / antibody, 40 micromoles, 800 μL) was added to 10 mL of Herceptin-C239i antibody (40 mg, 267 nanomoles) in a reduction buffer (containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA)) and the final antibody concentration was 4.0 mg / mL. The reduction mixture was reacted in an orbital shaker at room temperature with gentle (60 rpm) shaking for 4 hours and 45 minutes (or until complete reduction was observed by UHPLC). The reduced antibody buffer was exchanged into a reoxidation buffer containing PBS and 1 mM EDTA via spin filter centrifugation to remove all excess reducing agent. A solution of 50 mM dehydroascorbic acid (DHAA, 20 molar equivalents / antibody, 5.33 micromoles, 106.7 μL) in DMSO was added and the reoxidation mixture was allowed to react at room temperature with gentle (60 rpm) shaking for 16 hours, with an antibody concentration of 4 mg / mL (or more DHAA was added for longer reaction times until complete reoxidation of cysteine thiols was observed by UHPLC to reform interchain cysteine disulfides). The reoxidation mixture was then sterile filtered and diluted in conjugation buffer containing PBS and 1 mM EDTA to a final antibody concentration of 3.6 mg / mL. Compound 1 was added as a DMSO solution (10 molar equivalents / antibody, 1.33 micromoles in 0.55 mL DMSO) to 5.0 mL of the reoxidized antibody solution (20 mg, 133 nanomoles) with a final DMSO concentration of 10% (v / v). The solution was mixed for 2 hours at room temperature and the conjugate was then quenched by addition of N-acetylcysteine (6.67 micromolar, 67 μL at 100 mM) and then purified by spin filtration into PBS using a 15 mL Amicon Ultracell 30 kDa MWCO spin filter, sterile filtered and analyzed.
[0606] UHPLC analysis using a Thermo Scientific MAbPac 50 mm x 2.1 mm column on a Shimadzu Prominence system with a gradient elution of water and acetonitrile showed unconjugated light chain, and a mixture of unconjugated heavy chain and heavy chains attached to a single molecule of Compound 1 at 214 nm and 330 nm on a reduced sample of ConjA (Compound 1 specific), consistent with a drug / antibody ratio (DAR) of 1.89 molecules of Compound 1 per antibody.
[0607] UHPLC analysis was performed on a Shimadzu Prominence system using a Tosoh Bioscience TSKgel SuperSW mAb HTP 4μm 4.6x150mm column (with a 4μm 3.0x 20mm guard column) and eluted with 0.3mL / min of sterile filtered SEC buffer (containing 200mM potassium phosphate pH 6.95, 250mM potassium chloride and 10% isopropanol (v / v)), showing a monomer purity of 98% at 280nm on the ConjA sample. UHPLC SEC analysis yielded a final ConjA concentration of 2.14mg / mL in 6.5mL, and the mass of ConjA obtained was 13.9mg (70% yield).
[0608] ConjA*
[0609] A solution of 10 mM tris(2-carboxyethyl)phosphine (TCEP) in phosphate buffered saline pH 7.4 (PBS) (10 molar equivalents / antibody, 400 nanomoles, 40 μL) was added to a solution of 2.4 mL of trastuzumab antibody (6 mg, 40 nanomoles) in reducing buffer (PBS and 1 mM ethylenediaminetetraacetic acid (EDTA)) and the final antibody concentration was 2.5 mg / mL. The reduction mixture was reacted in an orbital shaker at room temperature with gentle (60 rpm) shaking for 16 hours (or until complete reduction was observed by UHPLC). The reduced antibody solution was buffer exchanged (to remove all excess reducing agent) into a conjugation buffer containing PBS and 1 mM EDTA via spin filter centrifugation, and the final antibody concentration was 2.0 mg / mL. Compound 1 was added as a DMSO solution (20 molar equivalents / antibody, 400 nanomoles in 0.15 mL DMSO) to 1.35 mL of the reduced antibody solution (3 mg, 20 nanomoles) with a final DMSO concentration of 10% (v / v). The solution was mixed at room temperature for 2 hours, then the conjugate was quenched by adding N-acetyl cysteine (2 micromoles, 20 μL at 100 mM), then purified by centrifugation on a 15 mL Amicon Ultracell 30 KDa MWCO spin filter, sterile filtered and analyzed.
[0610] UHPLC analysis was performed on a Shimadzu Prominence system using a Thermo Fisher Scientific MAbPac 50 mm x 2.1 mm column with a gradient elution of water and acetonitrile, showing unconjugated light chain, a mixture of light chains attached to a single molecule of compound 1, unconjugated heavy chain, and heavy chains attached to up to three molecules of compound 1 at 214 nm and 330 nm on a reduced sample of ConjA* (compound 1 specific), consistent with a drug / antibody ratio (DAR) of 7.89 molecules of compound 1 per antibody.
[0611] UHPLC analysis was performed on a Shimadzu Prominence system using a Tosoh Life Sciences TSKgel SuperSW mAb HTP 4μm 4.6x 150mm column (with a 4μm 3.0x20mm guard column) and eluted with 0.3mL / min of sterile filtered SEC buffer (containing 200mM potassium phosphate pH 6.95, 250mM potassium chloride and 10% isopropanol (v / v)), showing a monomer purity of 98.5% at 280nm on the ConjA* sample. UHPLC SEC analysis showed that the final ConjA* concentration in 1.25mL was 2.02mg / mL, and the mass of ConjA* obtained was 2.5mg (84% yield).
[0612] Conj
[0613] A solution of 10 mM tris(2-carboxyethyl)phosphine (TCEP) in phosphate buffered saline pH 7.4 (PBS) (10 molar equivalents / antibody, 3.56 micromoles, 356 μL) was added to a solution of 11.1 mL of trastuzumab antibody (53.4 mg, 356 nanomoles) in a reduction buffer (containing PBS, pH 7.4 and 1 mM ethylenediaminetetraacetic acid (EDTA)) and the final antibody concentration was 4.84 mg / mL. The reduction mixture was reacted in an orbital shaker at 37° C. with gentle (60 rpm) shaking for 1 hour and 30 minutes (or until complete reduction was observed by UHPLC). Compound 2 was added as a DMSO solution (15 molar equivalents / antibody, 5.1 micromoles in 1.2 mL DMSO) to 10.5 mL of the reduced antibody solution (50.8 mg, 339 nanomoles) and the final DMSO concentration was 10% (v / v). The solution was mixed at room temperature for 1 hour and 30 minutes, and then the conjugate was quenched by adding N-acetylcysteine (25.4 micromolar, 254 μL at 100 mM) and then quenched using a GE Healthcare HiLoad TM 26 / 600 column (filled with Superdex 200PG) in AKTA TMPurification was performed on a Start FPLC eluting with 2.6 mL / min PBS. Fractions corresponding to the ConjB monomer peak were pooled, concentrated, and buffer exchanged into 25 mM histidine 205 mM sucrose pH 6.0 buffer using a 15 mL Amicon Ultracell 50 KDa MWCO spin filter, sterile filtered, and analyzed.
[0614] UHPLC analysis was performed on a Shimadzu Prominence system using a Thermo Fisher Scientific MAbPac 50 mm x 2.1 mm column with a gradient elution of water and acetonitrile, showing unconjugated light chain, mixture of light chains with a single molecule of compound 2 attached, unconjugated heavy chain, and heavy chains with up to three molecules of compound 2 attached at 214 nm and 330 nm on a reduced sample of ConjB (compound 2 specific), consistent with a drug / antibody ratio (DAR) of 7.93 molecules of compound 2 per antibody.
[0615] UHPLC analysis was performed on a Shimadzu Prominence system using a Tosoh Life Sciences TSKgel SuperSW mAb HTP 4μm 4.6x 150mm column (with a 4μm 3.0x20mm guard column) and eluted with 0.3mL / min of sterile filtered SEC buffer (containing 200mM potassium phosphate pH 6.95, 250mM potassium chloride and 10% isopropanol (v / v)), showing a monomer purity of 98.9% at 280nm on the ConjB sample. UHPLC SEC analysis concluded that the final ConjB concentration in 16mL was 2.4mg / mL, and the mass of ConjB obtained was 38.4mg (84% yield).
[0616] Conj
[0617] A solution of 10 mM tris(2-carboxyethyl)phosphine (TCEP) in phosphate buffered saline pH 7.4 (PBS) (40 molar equivalents / antibody, 11.2 micromolar, 1.12 mL) was added to a solution of 20 mL of Herceptin-C239i antibody (42 mg, 280 nanomolar) in reduction buffer (containing PBS and 1 mM ethylenediaminetetraacetic acid (EDTA)) and the final antibody concentration was 2.1 mg / mL. The reduction mixture was reacted in an orbital shaker at room temperature with gentle (60 rpm) shaking for 16 hours (or until complete reduction was observed by UHPLC). The reduced antibody buffer was exchanged into a reoxidation buffer containing PBS and 1 mM EDTA via spin filter centrifugation to remove all excess reducing agent. A solution of 50 mM dehydroascorbic acid (DHAA, 30 molar equivalents / antibody, 7.0 micromoles, 141 μL) in DMSO was added to 22 mL of this reduced buffer-exchanged antibody (35.2 mg, 235 nanomoles), and the reoxidation mixture was reacted at room temperature with gentle (60 rpm) shaking for 2 hours and 30 minutes, with an antibody concentration of 1.6 mg / mL (or more DHAA was added, and the reaction time was longer until complete reoxidation of cysteine thiols was observed by UHPLC to reform interchain cysteine disulfides). The reoxidation mixture was then sterile filtered. Compound 6 was added to 11.0 mL of the reoxidized antibody solution (17.6 mg, 117 nanomoles) as a DMSO solution (20 molar equivalents / antibody, 2.3 micromoles in 1.36 mL DMSO), pH was adjusted with 1.22 mL of 1M sodium bicarbonate, and final DMSO concentration was 10% (v / v) and 10% (v / v) 1M sodium bicarbonate. The solution was reacted for 2 hours with slight shaking at room temperature. The conjugate was then quenched by adding N-acetylcysteine (12 micromoles, 117 μL at 100 mM), then purified and buffer exchanged to 25 mM histidine 205 mM sucrose pH 6.0 buffer using a 15 mL Amicon Ultracell 50 kDa MWCO spin filter, sterile filtered and analyzed.
[0618] UHPLC analysis was performed on a Shimadzu Prominence system using a Sepax Proteomix HIC Butyl NP5 4.6 x 35mm 5μm column eluted with a gradient of 25mM sodium phosphate, 1.5M ammonium sulfate pH 7.4 buffer, and 20% acetonitrile (v / v) in 25mM sodium phosphate pH 7.4 buffer. The intact sample of ConjC showed attachment of unconjugated and conjugated antibody to one or two molecules of compound 6 at 214nm and 330nm (compound 6 specific), consistent with a drug / antibody ratio (DAR) of 1.42 molecules of compound 6 per antibody.
[0619] UHPLC analysis was performed on a Shimadzu Prominence system using a Tosoh Life Sciences TSKgel SuperSW mAb HTP 4μm 4.6x 150mm column (with a 4μm 3.0x20mm guard column) and eluted with 0.3mL / min of sterile filtered SEC buffer (containing 200mM potassium phosphate pH 6.95, 250mM potassium chloride and 10% isopropanol (v / v)), showing a monomer purity of 98% at 280nm on the ConjC sample. UHPLC SEC analysis showed that the final ConjC concentration in 10.1mL was 1.06mg / mL, and the mass of ConjC obtained was 10.7mg (61% yield).
[0620] Example 13 - In vitro assay
[0621] Solid test materials were dissolved in DMSO to a 2 mM stock solution, from which eight serial dilutions were made at a 1:10 ratio in DMSO and stored at -20°C until use.
[0622] Adherent NCI-N87 cells were washed with D-PBS and detached with trypsin-EDTA, and then counted using an automated cell counter (LUNA-II TM ) Cell density and viability were determined in duplicate by trypan blue exclusion assay. Cell suspension was incubated in growth medium (containing Glutamax + 10% (v / v) HyClone TM Dilute to 1x 10 in RPMI 1640 containing fetal bovine serum 5 100 μl of the sample was then aliquoted into 2 replicate wells of a sterile 96-well microplate and incubated at 37°C CO. 2 At the end of the incubation period (7 days), the cells were cultured in a 5% aerated incubator. TM Cell viability was measured by aqueous One (MTS) assay, which was dispensed at 20 μl / well and incubated at 37°C, 5% CO 2 Incubate for 4 hours at 4 °C. TM The plate was read on a multilabel microplate reader (Perkin Elmer) using absorbance at 490 nm.
[0623] Cell viability was calculated by comparing the average absorbance of two replicate wells from each sample to the average absorbance of two control wells treated with DMSO alone (100%). IC was determined by fitting each data set to a sigmoidal dose-response curve with a variable slope using a nonlinear curve fitting algorithm on GraphPad Prism software (San Diego, CA). 50 .
[0624] All experiments in this report were performed and tested in three independent experiments. Data are reported as the average of three independent replicates.
[0625] <![CDATA[IC 50 (nM)]]> I11 0.3854
[0626] Example 14 - ADC in vitro assay
[0627] The concentration and viability of cells from subconfluent (80%-90% confluent) T75 flasks were measured by trypan blue staining and analyzed using LUNA-II TM Count the cells using an automated cell counter. Dilute the cells to 2 x 10 5 / ml, dispensed (50 μl per well) in a 96-well flat-bottom plate.
[0628] A stock solution (1 ml) of antibody drug conjugate (ADC) (20 μg / ml) was prepared by diluting filter-sterilized ADC into cell culture medium. A set of 8 x 10-fold dilutions of the stock ADC was prepared in a 24-well plate by serially transferring 100 μl into 900 μl of cell culture medium. The ADC dilutions (50 μl per well) were dispensed into 4 replicate wells of a 96-well plate containing 50 μl of previously seeded cell suspension. Control wells received 50 μl of cell culture medium. The 96-well plate containing cells and ADC was incubated at 37°C in a CO 2 Incubate in a gassed incubator for the exposure time.
[0629] At the end of the incubation period, cell viability was measured by MTS assay. MTS (Promega) was dispensed (20 μl per well) into each well and incubated at 4 °C for 24 h. 2 Incubate at 37°C in a gas-filled incubator for 4 hours. Well absorbance was measured at 490 nm. Cell survival percentage was calculated from the average absorbance of 4 ADC-treated wells and the average absorbance of 4 control untreated wells (100%). IC was determined from dose-response data using GraphPad Prism using a nonlinear curve fitting algorithm (sigmoidal dose-response curve with variable slope). 50 .
[0630] The incubation time of ADC for MDA-MB-468 was 4 days, and that for NCI-N87 was 7 days. TM MDA-MB-468 and NCI-N87 were cultured in RPMI1640 with fetal bovine serum. NCI-N87 is a Her2-expressing cell line, while MDA-MB-468 is a Her2-negative cell line.
[0631] <![CDATA[EC 50 (μg / ml)]]> NCI-N87 MDA-MB-468 Conj 0.1176 >10 ConjA* 0.01634 >10 Conj 0.01857 >10 Conj 0.1452 >10
[0632] Example 15 - ADC in vivo assay
[0633] Methods and Materials
[0634] Mouse
[0635] Female severe combined immunodeficient mice (Fox Chase SCID TM , CB17 / Icr-Prkdcscid / IcoIcrCrl, Charles River) were eight weeks old and had a body weight (BW) range of 14.5 to 20.0 g on day 1 of the study. Animals were fed ad libitum water (reverse osmosis, 1 ppm Cl), and modified NIH 31 and Irradiated Lab Diet TM (consisting of 18.0% crude protein, 5.0% crude fat, and 5.0% crude fiber). Mice were housed in irradiated Enrich-o'cobsTM laboratory animal bedding in static microisolators with a 12-hour light cycle at 20°C-22°C and 40%-60% humidity. CR Discovery Services adhered specifically to the recommendations of the Guide for the Care and Use of Laboratory Animals regarding restraint, housing, surgical procedures, feed and fluid supervision, and veterinary care. The animal care and use program of CR Discovery Services has been accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International, which ensures adherence to generally recognized standards for the care and use of laboratory animals.
[0636] Tumor cell culture
[0637] Human NCI-N87 gastric lymphoma cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units / mL penicillin, 100 μg / mL streptomycin sulfate, and 25 μg / mL gentamicin. The cells were incubated at 37°C in 5% CO. 2 The cells were grown in tissue culture flasks in a humidified incubator with an atmosphere of 95% air.
[0638] In vivo implantation and tumor growth
[0639] NCI-N87 cells for implantation were harvested during the logarithmic growth phase and resuspended in 50% Matrigel TM On the day of tumor implantation, each test mouse was injected subcutaneously in the right flank with 1×10 7 cells (0.1 mL of cell suspension), and when the average size is close to 100 to 150 mm 3 After 12 days (designated as day 1 of the study), the mice were divided into 14 groups based on the calculated tumor size, 7 groups were designated for efficacy evaluation (n=10), and 7 groups were designated for sample collection (n=3), each group consisted of a single tumor volume ranging from 108 to 172 mm 3 The average tumor volume of the group was 120-124 mm 3 Tumors were measured in two dimensions using calipers, and volumes were calculated using the following formula:
[0640] Tumor volume (mm 3 )=(w 2 xl) / 2
[0641] Where w = width of the tumor and l = length of the tumor in mm. You can assume that 1 mg is equal to 1 mm 3 Tumor weight was estimated from tumor volume.
[0642] Therapeutic agents
[0643] ConjA* was stored at 4°C protected from light. Sterile PBS was used to dose the vehicle control group.
[0644] treat
[0645] On day 1 of the study, female SCID mice bearing established NCI-N87 xenografts were grouped. Aliquots of the stock solution were diluted to the appropriate concentration with PBS. The agent was administered once via tail vein injection on day 1. The dose volume was 0.2 mL per 20 grams of body weight (10 mL / kg) and was proportional to the body weight of each animal.
[0646] Group 1 mice received PBS vehicle and served as a control group. Group 2 received 4 mg / kg of ConjA*.
[0647] Tumors were measured twice weekly using calipers when the tumor reached 800 mm in each animal. 3Each animal was euthanized at the end point volume of 100 μg / ml or at the end of the study (Day 68), whichever came first. Animals withdrawn from the study due to tumor volume endpoint were recorded as euthanized due to tumor progression (TP), and the date of euthanasia was recorded.
[0648] Criteria for extinction reactions
[0649] Treatment efficacy can be determined based on the incidence and magnitude of regression responses observed during the study. Treatment may result in partial regression (PR) or complete regression (CR) of tumors in animals. In a PR response, three consecutive measurements of tumor volume during the study are 50% or less of the day 1 tumor volume, and the tumor volume is equal to or greater than 13.5 mm in one or more of these three measurements. 3 In a CR response, the tumor volume was less than 13.5 mm on three consecutive measurements during the study. 3 Animals were scored only one PR or CR event during the study, and CR was scored if both PR and CR criteria were met. Animals with a CR response at study termination were additionally classified as tumor-free survivors (TFS). Animals were monitored for regression responses.
[0650] toxicity
[0651] Animals were weighed daily on days 1-5 and then twice weekly until study completion. Mice were observed frequently for overt signs of any adverse, treatment-related (TR) side effects, and clinical signs were recorded when observed. Individual body weights were monitored per protocol, and animals that lost more than 30% of body weight on any one measurement or more than 25% of body weight on three consecutive measurements were euthanized as TR deaths. Group mean body weight loss was also monitored per CR Discovery Services protocol. Acceptable toxicity was defined as less than 20% group mean body weight (BW) loss during the study, and no more than 10% TR deaths.
[0652] result
[0653] Figure 1 Mean tumor growth graphs are shown, where:
[0654] vehicle ● ConjA* ◆
[0655] Group 1 mice received PBS vehicle ivqd x 1 and served as the control group. The median TTE for Group 1 was 24.8 days. All control tumors reached 800 mm 3 end.
[0656] Group 2 received ConjA* at 4 mg / kg ivqd x 1. CR was observed in all 10 mice at the end of the study, which were otherwise classified as TFS.
[0657] The nadir body weight in the treatment group was -9.5% on study day 50. No TR deaths were observed.
[0658] Description of the Invention
[0659] 1. A compound having formula I:
[0660]
[0661] and its salts and solvates, wherein R L is a linker for attachment to the Ligand unit, the linker being selected from:
[0662] (ia):
[0663]
[0664] in
[0665] Q is:
[0666] Where Q X such that Q is an amino acid residue, a dipeptide residue, a tripeptide residue or a tetrapeptide residue;
[0667] X is:
[0668]
[0669] wherein a=0 to 5, b1=0 to 16, b2=0 to 16, c1=0 or 1, c2=0 or 1, d=0 to 5, wherein at least b1 or b2=0 and at least c1 or c2=0;
[0670] G L is a linker for attachment to the Ligand unit;
[0671] (ib):
[0672]
[0673] Where R L1 and R L2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropene or cyclobutene group; and
[0674] e is 0 or 1.
[0675] 2. A compound according to statement 1, wherein R L Has formula Ia.
[0676] 3. The compound according to statement 2, wherein Q is an amino acid residue.
[0677] 4. A compound according to statement 3, wherein Q is selected from the group consisting of: Phe, Lys, Val, Ala, Cit, Leu, Ile, Arg, and Trp.
[0678] 5. The compound according to statement 2, wherein Q is a dipeptide residue.
[0679] 6. A compound according to Statement 5, wherein Q is selected from:
[0680] NH -Phe-Lys- C=O ,
[0681] NH -Val-Ala- C=O ,
[0682] NH -Val-Lys- C=O ,
[0683] NH -Ala-Lys- C=O ,
[0684] NH -Val-Cit- C=O ,
[0685] NH -Phe-Cit- C=O ,
[0686] NH -Leu-Cit- C=O ,
[0687] NH -Ile-Cit- C=O ,
[0688] NH -Phe-Arg- C=O ,
[0689] NH -Trp-Cit- C=O ,and
[0690] NH -Gly-Val- C=O .
[0691] 7. A compound according to statement 6, wherein Q is selected from NH -Phe-Lys- C=O , NH -Val-Cit-C=O and NH -Val-Ala- C=O .
[0692] 8. A compound according to statement 2, wherein Q is a tripeptide residue.
[0693] 9. A compound according to Statement 8, wherein Q is selected from:
[0694] NH -Glu-Val-Ala- C=O ,
[0695] NH -Glu-Val-Cit- C=O ,
[0696] NH -αGlu-Val-Ala- C=O ,and
[0697] NH -αGlu-Val-Cit- C=O .
[0698] 10. A compound according to statement 2, wherein Q is a tetrapeptide residue.
[0699] 11. A compound according to Statement 10, wherein Q is selected from:
[0700] NH -Gly-Gly-Phe-Gly C=O ;as well as
[0701] NH -Gly-Phe-Gly-Gly C=O .
[0702] 12. A compound according to statement 11, wherein Q is:
[0703] NH -Gly-Gly-Phe-Gly C=O .
[0704] 13. A compound according to any one of Statements 2 to 12, wherein a is 0 to 3.
[0705] 14. A compound according to statement 13, wherein a is 0 or 1.
[0706] 15. A compound according to statement 13, wherein a is 0.
[0707] 16. A compound according to any one of Statements 2 to 15, wherein b1 is 0 to 8.
[0708] 17. A compound according to Statement 16, wherein b1 is 0.
[0709] 18. A compound according to Statement 16, wherein b1 is 2.
[0710] 19. A compound according to Statement 16, wherein b1 is 3.
[0711] 20. A compound according to Statement 16, wherein b1 is 4.
[0712] 21. A compound according to Statement 16, wherein b1 is 5.
[0713] 22. A compound according to Statement 16, wherein b1 is 8.
[0714] 23. A compound according to any one of Statements 2 to 15 and 17, wherein b2 is 0 to 8.
[0715] 24. A compound according to Statement 23, wherein b2 is 0.
[0716] 25. A compound according to Statement 23, wherein b2 is 2.
[0717] 26. A compound according to Statement 23, wherein b2 is 3.
[0718] 27. A compound according to Statement 23, wherein b2 is 4.
[0719] 28. A compound according to Statement 23, wherein b2 is 5.
[0720] 29. A compound according to Statement 23, wherein b2 is 8.
[0721] 30. A compound according to any one of Statements 2 to 29, wherein c1 is 0.
[0722] 31. A compound according to any one of Statements 2 to 29, wherein c1 is 1.
[0723] 32. A compound according to any one of Statements 2 to 31, wherein c2 is 0.
[0724] 33. A compound according to any one of Statements 2 to 30, wherein c2 is 1.
[0725] 34. A compound according to any one of Statements 2 to 33, wherein d is 0 to 3.
[0726] 35. A compound according to statement 34, wherein d is 1 or 2.
[0727] 36. A compound according to Statement 34, wherein d is 2.
[0728] 37. A compound according to any one of Statements 2 to 33, wherein d is 5.
[0729] 38. A compound according to any one of Statements 2 to 12, wherein a is 0, b1 is 0, c1 is 1, c2 is 0 and d is 2, and b2 is from 0 to 8.
[0730] 39. A compound according to statement 38, wherein b2 is 0, 2, 3, 4, 5 or 8.
[0731] 40. A compound according to any one of Statements 2 to 12, wherein a is 1, b2 is 0, c1 is 0, c2 is 0 and d is 0, and b1 is from 0 to 8.
[0732] 41. A compound according to statement 40, wherein b1 is 0, 2, 3, 4, 5 or 8.
[0733] 42. A compound according to any one of Statements 2 to 12, wherein a is 0, b1 is 0, c1 is 0, c2 is 0 and d is 1, and b2 is from 0 to 8.
[0734] 43. A compound according to statement 42, wherein b2 is 0, 2, 3, 4, 5 or 8.
[0735] 44. A compound according to any one of Statements 2 to 12, wherein b1 is 0, b2 is 0, c1 is 0, c2 is 0, one of a and d is 0, and the other of a and d is from 1 to 5.
[0736] 45. A compound according to statement 44, wherein the other of a and d is 1 or 5.
[0737] 46. A compound according to any one of Statements 2 to 12, wherein a is 1, b2 is 0, c1 is 0, c2 is 1, d is 2, and b1 is from 0 to 8.
[0738] 47. A compound according to statement 46, wherein b1 is 0, 2, 3, 4, 5 or 8.
[0739] 48. A compound according to any one of Statements 2 to 47, wherein G L Selected from
[0740]
[0741]
[0742] Where Ar represents C 5-6 arylene group, and X represents C 1-4 alkyl.
[0743] 49. A compound according to statement 48, wherein G L Selected from G L1-1 and G L1-2 .
[0744] 50. A compound according to statement 48, wherein G L It's G L1-1 .
[0745] 51. A compound according to statement 1, wherein R L Has formula Ib.
[0746] 52. A compound according to statement 51, wherein R L1 and R L2 Both are H.
[0747] 53. A compound according to statement 51, wherein R L1 is H and R L2 It's methyl.
[0748] 54. A compound according to statement 51, wherein R L1 and R L2 Both are methyl groups.
[0749] 55. A compound according to statement 51, wherein R L1 and R L2 Together with the carbon atom to which they are bonded they form a cyclopropene group.
[0750] 56. A compound according to statement 51, wherein R L1 and R L2 Together with the carbon atom to which they are bonded they form a cyclobutene group.
[0751] 57. A compound according to any one of Statements 51 to 56, wherein e is 0.
[0752] 58. A compound according to any one of Statements 51 to 56, wherein e is 1.
[0753] 59. A conjugate having formula IV:
[0754] L-(D L ) p (IV)
[0755] or a pharmaceutically acceptable salt or solvate thereof, wherein L is a ligand unit (ie, a targeting agent), D L is a Drug Linker unit having Formula III:
[0756]
[0757] R LL is a linker connected to the Ligand unit, the linker being selected from
[0758] (ia'):
[0759]
[0760] wherein Q and X are as defined in any one of Statements 1 to 47 and G LL is a linker attached to the Ligand unit; and
[0761] (ib'):
[0762]
[0763] Where R L1 and R L2 is as defined in any of statements 1 and 52 to 56; and
[0764] p is an integer from 1 to 20.
[0765] 60. The conjugate according to statement 59, wherein G LL Selected from:
[0766]
[0767]
[0768] Where Ar represents C 5-6 arylene group, and X represents C 1-4 alkyl.
[0769] 61. The conjugate according to statement 60, wherein G LL Selected from G LL1-1 and G LL1-2 .
[0770] 62. The conjugate according to statement 61, wherein G LL It's G LL1-1 .
[0771] 63. A conjugate according to any one of Statements 59 to 62, wherein the Ligand unit is a cell binding agent.
[0772] 64. The conjugate according to any one of Statements 59 to 62, wherein the Ligand unit is an antibody or an active fragment thereof.
[0773] 65. The conjugate according to statement 64, wherein the antibody or antibody fragment is an antibody or antibody fragment to a tumor-associated antigen.
[0774] 66. The conjugate according to statement 65, wherein the antibody or antibody fragment is an antibody that binds to one or more tumor-associated antigens or cell surface receptors selected from the following (1)-(89):
[0775] (1) BMPR1B;
[0776] (2) E16;
[0777] (3) STEAP1;
[0778] (4)0772P;
[0779] (5)MPF;
[0780] (6) Napi3b;
[0781] (7) Sema 5b;
[0782] (8)PSCA hlg;
[0783] (9) ETBR;
[0784] (10)MSG783;
[0785] (11) STEAP2;
[0786] (12)TrpM4;
[0787] (13) CRIPTO;
[0788] (14)CD21;
[0789] (15) CD79b;
[0790] (16) FcRH2;
[0791] (17) HER2;
[0792] (18) NCA;
[0793] (19) MDP;
[0794] (20) IL20R-α;
[0795] (21) Brevicin;
[0796] (22) EphB2R;
[0797] (23)ASLG659;
[0798] (24) PSCA;
[0799] (25)GEDA;
[0800] (26) BAFF-R;
[0801] (27)CD22;
[0802] (28)CD79a;
[0803] (29)CXCR5;
[0804] (30)HLA-DOB;
[0805] (31)P2X5;
[0806] (32)CD72;
[0807] (33)LY64;
[0808] (34)FcRH1;
[0809] (35)IRTA2;
[0810] (36)TENB2;
[0811] (37)PSMA-FOLH1;
[0812] (38)SST;
[0813] (38.1)SSTR2;
[0814] (38.2)SSTR5;
[0815] (38.3)SSTR1;
[0816] (38.4)SSTR3;
[0817] (38.5)SSTR4;
[0818] (39)ITGAV;
[0819] (40)ITGB6;
[0820] (41)CEACAM5;
[0821] (42)MET;
[0822] (43)MUC1;
[0823] (44)CA9;
[0824] (45)EGFRvIII;
[0825] (46)CD33;
[0826] (47)CD19;
[0827] (48)IL2RA;
[0828] (49) AXL;
[0829] (50)CD30-TNFRSF8;
[0830] (51) BCMA-TNFRSF17;
[0831] (52) CT Ags-CTA;
[0832] (53) CD174 (Lewis Y)-FUT3;
[0833] (54)CLEC14A;
[0834] (55) GRP78-HSPA5;
[0835] (56) CD70;
[0836] (57) Stem cell specific antigens;
[0837] (58)ASG-5;
[0838] (59)ENPP3;
[0839] (60)PRR4;
[0840] (61)GCC-GUCY2C;
[0841] (62)Liv-1-SLC39A6;
[0842] (63)5T4;
[0843] (64)CD56-NCMA1;
[0844] (65) CanAg;
[0845] (66)FOLR1;
[0846] (67)GPNMB;
[0847] (68)TIM-1-HAVCR1;
[0848] (69) RG-1 / prostate tumor target Mindin-Mindin / RG-1;
[0849] (70) B7-H4-VTCN1;
[0850] (71)PTK7;
[0851] (72)CD37;
[0852] (73)CD138-SDC1;
[0853] (74) CD74;
[0854] (75) tight junction protein-CL;
[0855] (76) EGFR;
[0856] (77) Her3;
[0857] (78)RON-MST1R;
[0858] (79)EPHA2;
[0859] (80)CD20-MS4A1;
[0860] (81) tenascin C-TNC;
[0861] (82) FAP;
[0862] (83)DKK-1;
[0863] (84)CD52;
[0864] (85)CS1-SLAMF7;
[0865] (86) Endoglin-ENG;
[0866] (87) Annexin A1-ANXA1;
[0867] (88) V-CAM (CD106)-VCAM1;
[0868] (89)ASCT2(SLC1A5).
[0869] 67. The conjugate according to any one of statements 64 to 66, wherein the antibody or antibody fragment is a cysteine engineered antibody.
[0870] 684. The conjugate according to any one of statements 64 to 67, wherein the drug loading (p) of the drug (D) to the antibody (Ab) is an integer from 1 to about 10.
[0871] 69. The conjugate of statement 68, wherein p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0872] 70. A mixture of conjugates according to any one of Statements 64 to 69, wherein the average drug loading per antibody in the mixture of antibody-drug conjugates is from about 1 to about 10.
[0873] 71. A conjugate or mixture according to any one of statements 59 to 70 for use in therapy.
[0874] 72. A pharmaceutical composition comprising a conjugate or mixture according to any one of Statements 59 to 70 and a pharmaceutically acceptable diluent, carrier, or excipient.
[0875] 73. A conjugate or mixture according to any one of Statements 59 to 70, or a pharmaceutical composition according to Statement 72, for use in the treatment of a proliferative disease in a subject.
[0876] 74. The conjugate, mixture or pharmaceutical composition according to statement 73, wherein the disease is cancer.
[0877] 75. Use of a conjugate or mixture according to any one of statements 59 to 70, or a pharmaceutical composition according to statement 72, in a method of medical treatment.
[0878] 76. A method of medical treatment comprising administering to a patient a pharmaceutical composition according to statement 72.
[0879] 77. The method according to statement 76, wherein the method of medical treatment is for treating cancer.
[0880] 78. The method according to statement 77, wherein a chemotherapeutic agent is administered to the patient in combination with the conjugate.
[0881] 79. Use of a conjugate or mixture according to any one of statements 59 to 70 in a method for the manufacture of a medicament for the treatment of a proliferative disease.
[0882] 80. A method of treating a mammal suffering from a proliferative disease, the method comprising administering an effective amount of a conjugate or mixture according to any one of Statements 59 to 70, or a pharmaceutical composition according to Statement 72.
[0883] 81. Compound A:
[0884]
[0885] As a single enantiomer or in enantiomerically enriched form.
[0886] 82. A compound of formula VI:
[0887]
[0888] wherein Q is as defined in any one of statements 1 and 3 and 12. Statement of the invention from the first priority application (P1)
[0889] P1-1. A compound having formula I:
[0890]
[0891] and its salts and solvates, wherein R L is a linker for attachment to a cell binding agent, the linker being selected from:
[0892] (ia):
[0893]
[0894] in
[0895] Q is:
[0896] Where Q X such that Q is an amino acid residue, a dipeptide residue or a tripeptide residue;
[0897] X is:
[0898]
[0899] Where a=0 to 5, b=0 to 16, c=0 or 1, d=0 to 5;
[0900] G L is a linker for attachment to the Ligand unit;
[0901] (ib):
[0902]
[0903] Where R L1 and R L2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropene or cyclobutene group; and
[0904] e is 0 or 1.
[0905] P1-2. A compound according to statement P1-1, wherein R L It has the formula Ia.
[0906] P1-3. A compound according to statement P1-2, wherein Q is an amino acid residue.
[0907] P1-4. A compound according to statement P1-3, wherein Q is selected from: Phe, Lys, Val, Ala, Cit, Leu, Ile, Arg, and Trp.
[0908] P1-5. A compound according to statement P1-2, wherein Q is a dipeptide residue.
[0909] P1-6. A compound according to statement P1-5, wherein Q is selected from:
[0910] NH -Phe-Lys- C=O ,
[0911] NH -Val-Ala- C=O ,
[0912] NH -Val-Lys- C=O ,
[0913] NH Ala-Lys- C=O ,
[0914] NH -Val-Cit- C=O ,
[0915] NH -Phe-Cit- C=O ,
[0916] NH -Leu-Cit- C=O ,
[0917] NH -Ile-Cit- C=O ,
[0918] NH -Phe-Arg- C=O ,
[0919] NH -Trp-Cit- C=O ,and
[0920] NH -Gly-Val- C=O .
[0921] P1-7. A conjugate according to statement P1-6, wherein Q is selected from NH -Phe-Lys- C=O , NH -Val-Cit- C=O and NH -Val-Ala- C=O .
[0922] P1-8. A compound according to statement P1-2, wherein Q is a tripeptide residue.
[0923] P1-9. A compound according to any one of statements P1-2 to P1-8, wherein a is 0 to 3.
[0924] P1-10. A compound according to statement P1-9, wherein a is 0 or 1.
[0925] P1-11. A compound according to statement P1-9, wherein a is 0.
[0926] P1-12. A compound according to any one of statements P1-2 to P1-11, wherein b is 0 to 8.
[0927] P1-13. A compound according to statement P1-12, wherein b is 0.
[0928] P1-14. A compound according to statement P1-12, wherein b is 4.
[0929] P1-15. A compound according to statement P1-12, wherein b is 8.
[0930] P1-16. A compound according to any one of statements P1-2 to P1-15, wherein c is 0.
[0931] P1-17. A compound according to any one of statements P1-2 to P1-15, wherein c is 1.
[0932] P1-18. A compound according to any one of statements P1-2 to P1-17, wherein d is 0 to 3.
[0933] P1-19. A compound according to statement P1-18, wherein d is 1 or 2.
[0934] P1-20. A compound according to statement P1-19, wherein d is 2.
[0935] P1-21. A compound according to any one of statements P1-2 to P1-8, wherein a is 0, c is 1 and d is 2, and b is 0, 4 or 8.
[0936] P1-22. A compound according to any one of statements P1-2 to P1-21, wherein G L Selected from
[0937]
[0938]
[0939] Where Ar represents C 5-6 arylene group, and X represents C 1-4 alkyl.
[0940] P1-23. A compound according to statement P1-22, wherein G L Selected from G L1-1 and G L1-2 .
[0941] P1-24. A compound according to statement P1-22, wherein G L It's G L1-1 .
[0942] P1-25. A compound according to statement P1-1, wherein R L Has formula Ib.
[0943] P1-26. A compound according to statement P1-25, wherein R L1 and R L2 Both are H.
[0944] P1-27. A compound according to statement P1-25, wherein R L1 is H and R L2 It's methyl.
[0945] P1-28. A compound according to statement P1-25, wherein R L1 and R L2 Both are methyl groups.
[0946] P1-29. A compound according to statement P1-25, wherein R L1 and R L2 Together with the carbon atom to which they are bonded they form a cyclopropene group.
[0947] P1-30. A compound according to statement P1-25, wherein R L1 and R L2 Together with the carbon atom to which they are bonded they form a cyclobutene group.
[0948] P1-31. A compound according to any one of statements P1-25 to P1-30, wherein e is 0.
[0949] P1-32. A compound according to any one of statements P1-25 to P1-30, wherein e is 1.
[0950] P1-33. A conjugate having formula IV:
[0951] L-(D L ) p (IV)
[0952] or a pharmaceutically acceptable salt or solvate thereof, wherein L is a ligand unit (ie, a targeting agent), D L is a Drug Linker unit having Formula III:
[0953]
[0954] R LL is a linker connected to the Ligand unit, the linker being selected from
[0955] (ia'):
[0956]
[0957] wherein Q and X are as defined in any of Statements P1-1 to P1-21 and G LL is a linker attached to the Ligand unit; and
[0958] (ib'):
[0959]
[0960] Where R L1 and R L2 is as defined in any of Statements P1-1 and P1-25 to P1-30; and
[0961] p is an integer from 1 to 20.
[0962] P1-34. A conjugate according to statement P1-33, wherein G LL Selected from:
[0963]
[0964]
[0965] Where Ar represents C 5-6 arylene group, and X represents C 1-4 alkyl.
[0966] P1-35. A conjugate according to statement P1-34, wherein G LL Selected from G LL1-1 and G LL1-2 .
[0967] P1-36. A conjugate according to statement P1-35, wherein G LL It's G LL1-1 .
[0968] P1-37. A conjugate according to any one of statements P1-33 to P1-36, wherein the cell binding agent is an antibody or an active fragment thereof.
[0969] P1-38. The conjugate according to statement P1-37, wherein the antibody or antibody fragment is an antibody or antibody fragment to a tumor-associated antigen.
[0970] P1-39. A conjugate according to statement P1-38, wherein the antibody or antibody fragment is an antibody that binds to one or more tumor-associated antigens or cell surface receptors selected from the following (1)-(88):
[0971] (1) BMPR1B;
[0972] (2) E16;
[0973] (3) STEAP1;
[0974] (4) 0772P;
[0975] (5) MPF;
[0976] (6) Napi3b;
[0977] (7) Sema 5b;
[0978] (8) PSCA hlg;
[0979] (9) ETBR;
[0980] (10) MSG783;
[0981] (11) STEAP2;
[0982] (12) TrpM4;
[0983] (13) CRIPTO;
[0984] (14) CD21;
[0985] (15) CD79b;
[0986] (16) FcRH2;
[0987] (17) HER2;
[0988] (18) NCA;
[0989] (19) MDP;
[0990] (20) IL20R-α;
[0991] (21) Shortening factor;
[0992] (22) EphB2R;
[0993] (23) ASLG659;
[0994] (24) PSCA;
[0995] (25) GEDA;
[0996] (26) BAFF-R;
[0997] (27) CD22;
[0998] (28) CD79a;
[0999] (29)CXCR5;
[1000] (30)HLA-DOB;
[1001] (31)P2X5;
[1002] (32)CD72;
[1003] (33)LY64;
[1004] (34)FcRH1;
[1005] (35)IRTA2;
[1006] (36)TENB2;
[1007] (37)PSMA-FOLH1;
[1008] (38)SST;
[1009] (38.1)SSTR2;
[1010] (38.2)SSTR5;
[1011] (38.3)SSTR1;
[1012] (38.4)SSTR3;
[1013] (38.5)SSTR4;
[1014] (39)ITGAV;
[1015] (40)ITGB6;
[1016] (41)CEACAM5;
[1017] (42)MET;
[1018] (43)MUC1;
[1019] (44)CA9;
[1020] (45)EGFRvIII;
[1021] (46)CD33;
[1022] (47)CD19;
[1023] (48)IL2RA;
[1024] (49)AXL;
[1025] (50)CD30-TNFRSF8;
[1026] (51) BCMA-TNFRSF17;
[1027] (52) CT Ags-CTA;
[1028] (53) CD174 (Lewis Y)-FUT3;
[1029] (54)CLEC14A;
[1030] (55) GRP78-HSPA5;
[1031] (56) CD70;
[1032] (57) Stem cell specific antigens;
[1033] (58)ASG-5;
[1034] (59)ENPP3;
[1035] (60)PRR4;
[1036] (61)GCC-GUCY2C;
[1037] (62)Liv-1-SLC39A6;
[1038] (63)5T4;
[1039] (64)CD56-NCMA1;
[1040] (65) CanAg;
[1041] (66)FOLR1;
[1042] (67)GPNMB;
[1043] (68)TIM-1-HAVCR1;
[1044] (69) RG-1 / prostate tumor target Mindin-Mindin / RG-1;
[1045] (70) B7-H4-VTCN1;
[1046] (71)PTK7;
[1047] (72)CD37;
[1048] (73)CD138-SDC1;
[1049] (74) CD74;
[1050] (75) tight junction protein-CL;
[1051] (76) EGFR;
[1052] (77) Her3;
[1053] (78)RON-MST1R;
[1054] (79)EPHA2;
[1055] (80)CD20-MS4A1;
[1056] (81) tenascin C-TNC;
[1057] (82) FAP;
[1058] (83)DKK-1;
[1059] (84)CD52;
[1060] (85)CS1-SLAMF7;
[1061] (86) Endoglin-ENG;
[1062] (87) Annexin A1-ANXA1;
[1063] (88) V-CAM (CD106)-VCAM1;
[1064] (89)ASCT2(SLC1A5).
[1065] P1-40. The conjugate according to any one of statements P1-37 to P1-39, wherein the antibody or antibody fragment is a cysteine engineered antibody.
[1066] P1-41. The conjugate according to any one of statements P1-37 to P1-40, wherein the drug loading (p) of the drug (D) to the antibody (Ab) is an integer from 1 to about 10.
[1067] P1-42. The conjugate according to statement P1-41, wherein p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[1068] P1-43. A mixture of conjugates according to any one of statements P1-33 to P1-42, wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is about 1 to about 10.
[1069] P1-44. A conjugate or mixture according to any one of statements P1-33 to P1-43 for use in therapy.
[1070] P1-45. A pharmaceutical composition comprising a conjugate or mixture according to any one of statements P1-33 to P1-43 and a pharmaceutically acceptable diluent, carrier, or excipient.
[1071] P1-46. The conjugate or mixture according to any one of statements P1-33 to P1-43, or the pharmaceutical composition according to statement P1-45, for use in the treatment of a proliferative disease in a subject.
[1072] P1-47. The conjugate or mixture according to statement P1-46, wherein the disease is cancer.
[1073] P1-48. Use of a conjugate or mixture according to any one of statements P1-33 to P1-43, or a pharmaceutical composition according to statement P1-45 in a method of medical treatment.
[1074] P1-49. A method of medical treatment comprising administering to a patient the pharmaceutical composition of statement P1-45.
[1075] P1-50. A method according to statement P1-49, wherein the method of medical treatment is used to treat cancer.
[1076] P1-51. The method according to statement P1-50, wherein a chemotherapeutic agent in combination with the conjugate is administered to the patient.
[1077] P1-52. Use of a conjugate or mixture according to any one of statements P1-33 to P1-43 in a method for the manufacture of a medicament for the treatment of a proliferative disease.
[1078] P1-53. A method of treating a mammal suffering from a proliferative disease, the method comprising administering an effective amount of a conjugate or mixture according to any one of statements P1-33 to P1-43, or a pharmaceutical composition according to statement P1-45.
[1079] P1-54. Compound A:
[1080]
[1081] In the form of a single enantiomer or in enantiomerically enriched form. Statement of the invention from the second priority application (P2)
[1082] P2-1. A compound having formula I:
[1083]
[1084] and its salts and solvates, wherein R Lis a linker for attachment to a cell binding agent, the linker being selected from:
[1085] (ia):
[1086]
[1087] in
[1088] Q is:
[1089] Where Q X such that Q is an amino acid residue, a dipeptide residue, a tripeptide residue or a tetrapeptide residue;
[1090] X is:
[1091]
[1092] Where a=0 to 5, b1=0 to 16, b2=0 to 16, c=0 or 1, d=0 to 5, wherein at least b1 or b2=0;
[1093] G L is a linker for attachment to the Ligand unit;
[1094] (ib):
[1095]
[1096] Where R L1 and R L2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropene or cyclobutene group; and
[1097] e is 0 or 1.
[1098] P2-2. A compound according to statement P2-1, wherein R L It has the formula Ia.
[1099] P2-3. A compound according to statement P2-2, wherein Q is an amino acid residue.
[1100] P2-4. A compound according to statement P2-3, wherein Q is selected from: Phe, Lys, Val, Ala, Cit, Leu, Ile, Arg, and Trp.
[1101] P2-5. A compound according to statement P2-2, wherein Q is a dipeptide residue.
[1102] P2-6. A compound according to statement P2-5, wherein Q is selected from:
[1103] NH -Phe-Lys- C=O,
[1104] NH -Val-Ala- C=O ,
[1105] NH -Val-Lys- C=O ,
[1106] NH -Ala-Lys- C=O ,
[1107] NH -Val-Cit- C=O ,
[1108] NH -Phe-Cit- C=O ,
[1109] NH -Leu-Cit- C=O ,
[1110] NH -Ile-Cit- C=O ,
[1111] NH -Phe-Arg- C=O ,
[1112] NH -Trp-Cit- C=O ,and
[1113] NH -Gly-Val- C=O .
[1114] P2-7. A compound according to statement P2-6, wherein Q is selected from NH -Phe-Lys- C=O , NH -Val-Cit- C=O and NH -Val-Ala- C=O .
[1115] P2-8. A compound according to statement P2-2, wherein Q is a tripeptide residue.
[1116] P2-9. A compound according to statement P2-8, wherein Q is selected from:
[1117] NH -Glu-Val-Ala- C=O ,
[1118] NH-Glu-Val-Cit- C=O ,
[1119] NH -αGlu-Val-Ala- C=O ,and
[1120] NH -αGlu-Val-Cit- C=O .
[1121] P2-10. A compound according to statement P2-2, wherein Q is a tetrapeptide residue.
[1122] P2-11. A compound according to statement P2-10, wherein Q is selected from:
[1123] NH -Gly-Gly-Phe-Gly C=O ;and
[1124] NH -Gly-Phe-Gly-Gly C=O .
[1125] P2-12. A compound according to statement P2-11, wherein Q is:
[1126] NH -Gly-Gly-Phe-Gly C=O .
[1127] P2-13. A compound according to any one of statements P2-2 to P2-12, wherein a is 0 to 3.
[1128] P2-14. A compound according to statement P2-13, wherein a is 0 or 1.
[1129] P2-15. A compound according to statement P2-13, wherein a is 0.
[1130] P2-16. A compound according to any one of statements P2-2 to P2-15, wherein b1 is 0 to 8.
[1131] P2-17. A compound according to statement P2-16, wherein b1 is 0.
[1132] P2-18. A compound according to statement P2-16, wherein b1 is 2.
[1133] P2-19. A compound according to statement P2-16, wherein b1 is 3.
[1134] P2-20. A compound according to statement P2-16, wherein b1 is 4.
[1135] P2-21. A compound according to statement P2-16, wherein b1 is 5.
[1136] P2-22. A compound according to statement P2-16, wherein b1 is 8.
[1137] P2-23. A compound according to any one of statements P2-2 to P2-15 and P2-17, wherein b2 is 0 to 8.
[1138] P2-24. A compound according to statement P2-23, wherein b2 is 0.
[1139] P2-25. A compound according to statement P2-23, wherein b2 is 2.
[1140] P2-26. A compound according to statement P2-23, wherein b2 is 3.
[1141] P2-27. A compound according to statement P2-23, wherein b2 is 4.
[1142] P2-28. A compound according to statement P2-23, wherein b2 is 5.
[1143] P2-29. A compound according to statement P2-23, wherein b2 is 8.
[1144] P2-30. A compound according to any one of statements P2-2 to P2-29, wherein c is 0.
[1145] P2-31. A compound according to any one of statements P2-2 to P2-29, wherein c is 1.
[1146] P2-32. A compound according to any one of statements P2-2 to P2-31, wherein d is 0 to 3.
[1147] P2-33. A compound according to statement P2-32, wherein d is 1 or 2.
[1148] P2-34. A compound according to statement P2-32, wherein d is 2.
[1149] P2-35. A compound according to any one of statements P2-2 to P2-12, wherein a is 0, b1 is 0, c is 1 and d is 2, and b2 is from 0 to 8.
[1150] P2-36. A compound according to statement P2-35, wherein b2 is 0, 2, 3, 4, 5 or 8.
[1151] P2-37. A compound according to any one of statements P2-2 to P2-12, wherein a is 1, b2 is 0, c is 0 and d is 0, and b1 is from 0 to 8.
[1152] P2-38. A compound according to statement P2-37, wherein b1 is 0, 2, 3, 4, 5 or 8.
[1153] P2-39. A compound according to any one of statements P2-2 to P2-12, wherein a is 0, b1 is 0, c is 0 and d is 1, and b2 is from 0 to 8.
[1154] P2-40. A compound according to statement P2-39, wherein b2 is 0, 2, 3, 4, 5 or 8.
[1155] P2-41. A compound according to any one of statements P2-2 to P2-12, wherein b1 is 0, b2 is 0, c is 0, one of a and d is 0, and the other of a and d is from 1 to 5.
[1156] P2-42. A compound according to statement P2-41, wherein the other of a and d is 1 or 5.
[1157] P2-43. A compound according to any one of statements P2-2 to P2-42, wherein G L Selected from
[1158]
[1159]
[1160] Where Ar represents C 5-6 arylene group, and X represents C 1-4 alkyl.
[1161] P2-44. A compound according to statement P2-43, wherein G L Selected from G L1-1 and G L1-2 .
[1162] P2-45. A compound according to statement P2-43, wherein G L It's G L1-1 .
[1163] P2-46. A compound according to statement P2-1, wherein R L Has formula Ib.
[1164] P2-47. A compound according to statement P2-46, wherein R L1 and R L2 Both are H.
[1165] P2-48. A compound according to statement P2-46, wherein R L1 is H and R L2 It's methyl.
[1166] P2-49. A compound according to statement P2-46, wherein R L1 and R L2 Both are methyl groups.
[1167] P2-50. A compound according to statement P2-46, wherein R L1 and R L2 Together with the carbon atom to which they are bonded they form a cyclopropene group.
[1168] P2-51. A compound according to statement P2-46, wherein R L1 and R L2 Together with the carbon atom to which they are bonded they form a cyclobutene group.
[1169] P2-52. A compound according to any one of statements P2-46 to P2-51, wherein e is 0.
[1170] P2-53. A compound according to any one of statements P2-46 to P2-51, wherein e is 1.
[1171] P2-54. A conjugate having formula IV:
[1172] L-(D L ) p (IV)
[1173] or a pharmaceutically acceptable salt or solvate thereof, wherein L is a ligand unit (ie, a targeting agent), D L is a Drug Linker unit having Formula III:
[1174]
[1175] R LL is a linker connected to the Ligand unit, the linker being selected from
[1176] (ia'):
[1177]
[1178] wherein Q and X are as defined in any of statements P2-1 to P2-42 and G LL is a linker attached to the Ligand unit; and
[1179] (ib'):
[1180]
[1181] Where R L1 and R L2 is as defined in any of statements P2-1 and P2-47 to P2-51; and
[1182] p is an integer from 1 to 20.
[1183] P2-55. A conjugate according to statement P2-54, wherein G LL Selected from:
[1184]
[1185] Where Ar represents C 5-6 arylene group, and X represents C 1-4 alkyl.
[1186] P2-56. A conjugate according to statement P2-55, wherein G LL Selected from G LL1-1 and G LL1-2 .
[1187] P2-57. A conjugate according to statement P2-56, wherein G LL It's G LL1-1 .
[1188] P2-58. A conjugate according to any one of statements P2-54 to P2-57, wherein the Ligand unit is an antibody or an active fragment thereof.
[1189] P2-59. The conjugate according to statement P2-58, wherein the antibody or antibody fragment is an antibody or antibody fragment to a tumor-associated antigen.
[1190] P2-60. A conjugate according to statement P2-59, wherein the antibody or antibody fragment is an antibody that binds to one or more tumor-associated antigens or cell surface receptors selected from the following (1)-(89):
[1191] (1) BMPR1B;
[1192] (2) E16;
[1193] (3) STEAP1;
[1194] (4)0772P;
[1195] (5)MPF;
[1196] (6) Napi3b;
[1197] (7) Sema 5b;
[1198] (8) PSCA hlg;
[1199] (9) ETBR;
[1200] (10) MSG783;
[1201] (11) STEAP2;
[1202] (12) TrpM4;
[1203] (13) CRIPTO;
[1204] (14) CD21;
[1205] (15) CD79b;
[1206] (16) FcRH2;
[1207] (17) HER2;
[1208] (18) NCA;
[1209] (19) MDP;
[1210] (20) IL20R-α;
[1211] (21) Shortening factor;
[1212] (22) EphB2R;
[1213] (23) ASLG659;
[1214] (24) PSCA;
[1215] (25) GEDA;
[1216] (26) BAFF-R;
[1217] (27) CD22;
[1218] (28) CD79a;
[1219] (29) CXCR5;
[1220] (30) HLA-DOB;
[1221] (31) P2X5;
[1222] (32) CD72;
[1223] (33) LY64;
[1224] (34) FcRH1;
[1225] (35) IRTA2;
[1226] (36)TENB2;
[1227] (37)PSMA-FOLH1;
[1228] (38)SST;
[1229] (38.1)SSTR2;
[1230] (38.2)SSTR5;
[1231] (38.3)SSTR1;
[1232] (38.4)SSTR3;
[1233] (38.5)SSTR4;
[1234] (39)ITGAV;
[1235] (40)ITGB6;
[1236] (41)CEACAM5;
[1237] (42)MET;
[1238] (43)MUC1;
[1239] (44)CA9;
[1240] (45)EGFRvIII;
[1241] (46)CD33;
[1242] (47)CD19;
[1243] (48)IL2RA;
[1244] (49)AXL;
[1245] (50)CD30-TNFRSF8;
[1246] (51)BCMA-TNFRSF17;
[1247] (52)CT Ags-CTA;
[1248] (53)CD174(Lewis Y)-FUT3;
[1249] (54)CLEC14A;
[1250] (55)GRP78-HSPA5;
[1251] (56)CD70;
[1252] (57) Stem cell specific antigens;
[1253] (58)ASG-5;
[1254] (59)ENPP3;
[1255] (60)PRR4;
[1256] (61)GCC-GUCY2C;
[1257] (62)Liv-1-SLC39A6;
[1258] (63)5T4;
[1259] (64)CD56-NCMA1;
[1260] (65) CanAg;
[1261] (66)FOLR1;
[1262] (67)GPNMB;
[1263] (68)TIM-1-HAVCR1;
[1264] (69) RG-1 / prostate tumor target Mindin-Mindin / RG-1;
[1265] (70) B7-H4-VTCN1;
[1266] (71)PTK7;
[1267] (72)CD37;
[1268] (73)CD138-SDC1;
[1269] (74) CD74;
[1270] (75) tight junction protein-CL;
[1271] (76) EGFR;
[1272] (77) Her3;
[1273] (78)RON-MST1R;
[1274] (79)EPHA2;
[1275] (80)CD20-MS4A1;
[1276] (81) tenascin C-TNC;
[1277] (82) FAP;
[1278] (83)DKK-1;
[1279] (84)CD52;
[1280] (85)CS1-SLAMF7;
[1281] (86) Endoglin-ENG;
[1282] (87) Annexin A1-ANXA1;
[1283] (88) V-CAM (CD106)-VCAM1;
[1284] (89)ASCT2(SLC1A5).
[1285] P2-61. A conjugate according to any one of statements P2-58 to P2-60, wherein the antibody or antibody fragment is a cysteine engineered antibody.
[1286] P2-62. The conjugate according to any one of statements P2-58 to P2-61, wherein the drug loading (p) of the drug (D) to the antibody (Ab) is an integer from 1 to about 10.
[1287] P2-63. A conjugate according to statement P2-62, wherein p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[1288] P2-64. A mixture of conjugates according to any one of statements P2-58 to P2-63, wherein the average drug loading per antibody in the mixture of antibody-drug conjugates is about 1 to about 10.
[1289] P2-65. A conjugate or mixture according to any one of statements P2-54 to P2-64 for use in therapy.
[1290] P2-66. A pharmaceutical composition comprising a conjugate or mixture according to any one of statements P2-54 to P2-64 and a pharmaceutically acceptable diluent, carrier, or excipient.
[1291] P2-67. The conjugate or mixture according to any one of statements P2-54 to P2-64, or the pharmaceutical composition according to statement P2-66, for use in the treatment of a proliferative disease in a subject.
[1292] P2-68. The conjugate, mixture or pharmaceutical composition according to statement P2-67, wherein the disease is cancer.
[1293] P2-69. Use of a conjugate or mixture according to any one of statements P2-54 to P2-64, or a pharmaceutical composition according to statement P2-66 in a method of medical treatment.
[1294] P2-70. A method of medical treatment comprising administering to a patient the pharmaceutical composition of statement P2-66.
[1295] P2-71. A method according to statement P2-70, wherein the method of medical treatment is used to treat cancer.
[1296] P2-72. The method according to statement P2-71, wherein a chemotherapeutic agent in combination with the conjugate is administered to the patient.
[1297] P2-73. Use of a conjugate or mixture according to any one of statements P2-54 to P2-64 in a method for the manufacture of a medicament for the treatment of a proliferative disease.
[1298] P2-74. A method of treating a mammal suffering from a proliferative disease, the method comprising administering an effective amount of a conjugate or mixture according to any one of statements P2-54 to P2-64, or a pharmaceutical composition according to statement P2-66.
[1299] P2-75. Compound A:
[1300]
[1301] As a single enantiomer or in enantiomerically enriched form.
Claims
1. A compound having formula I: and its salts, wherein R L is a linker for attachment to an antibody or an antigen-binding fragment of an antibody, the linker being selected from: (ia): in Q is: Where Q X Let Q be a dipeptide residue or a tetrapeptide residue, which is NH -Val-Ala- C=O or NH -Gly-Gly-Phe-Gly C=O , and the superscript C(=O) and NH It indicates the group to which the atom is bonded; X is: Where a=0, b1=0, b2=0 to 8, c1=0 or 1, c2=0, d=2 or 5; G L is a linker for attachment to an antibody or an antigen-binding fragment of an antibody, wherein G L yes (ib): Where R L1 and R L2 are independently selected from H and methyl; and e is 1.
2. The compound according to claim 1, wherein b2 is: (a) 0; or (b) 2; or (c) 3; or (d) 4; or (e) 5; or (f)8。 3. The compound according to claim 1 or claim 2, wherein c1 is 1.
4. The compound according to claim 1 or 2, in: (a) a is 0, b1 is 0, c1 is 1, c2 is 0 and d is 2, and b2 is 0, 2, 3, 4, 5 or 8; or (b) b1 is 0, b2 is 0, c1 is 0, c2 is 0, a is 0, and d is 5.
5. A conjugate having formula IV: L-(D L ) p (IV) or a pharmaceutically acceptable salt thereof, wherein L is a ligand unit, D L is a Drug Linker unit having Formula III: R LL is a linker connected to the Ligand unit, the linker being selected from (ia'): wherein Q and X are as defined in any one of claims 1 to 4 and G LL is a linker connected to the Ligand unit, where G LL yes: and (ib'): Where R L1 and R L2 is as defined in claim 1; and p is an integer from 1 to 10, And wherein the Ligand unit is an antibody or an active fragment thereof.
6. A pharmaceutical composition comprising the conjugate according to claim 5 and a pharmaceutically acceptable diluent, carrier, or excipient.
7. Use of the conjugate according to claim 5 or the pharmaceutical composition according to claim 6 in the preparation of a medicament for treating cancer in a subject.
